<?xml version="1.0" encoding="UTF-8"?><OAI-PMH
	xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd"><responseDate>2019-03-02T19:58:59Z</responseDate><request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:4642222" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request><GetRecord><record><header><identifier>oai:pubmedcentral.nih.gov:4642222</identifier><datestamp>2015-11-27</datestamp><setSpec>acssd</setSpec><setSpec>pmc-open</setSpec></header><metadata><article xmlns="https://jats.nlm.nih.gov/ns/archiving/1.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.0/ https://jats.nlm.nih.gov/archiving/1.0/xsd/JATS-archivearticle1.xsd" article-type="rapid-communication" xml:lang="EN">
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Biochemistry</journal-id>
      <journal-id journal-id-type="iso-abbrev">Biochemistry</journal-id>
      <journal-id journal-id-type="publisher-id">bi</journal-id>
      <journal-id journal-id-type="coden">bichaw</journal-id>
      <journal-title-group>
        <journal-title>Biochemistry</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0006-2960</issn>
      <issn pub-type="epub">1520-4995</issn>
      <publisher>
        <publisher-name>American
Chemical Society</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="accession">PMC4642222</article-id>
      <article-id pub-id-type="pmcid">PMC4642222</article-id>
      <article-id pub-id-type="pmc-uid">4642222</article-id>
      <article-id pub-id-type="pmid">26460884</article-id>
      <article-id pub-id-type="doi">10.1021/acs.biochem.5b00975</article-id>
      <article-categories>
        <subj-group>
          <subject>Accelerated Publication</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>G Protein-Coupled Receptors Directly Bind Filamin
A with High Affinity and Promote Filamin Phosphorylation</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author" id="ath1">
          <name>
            <surname>Tirupula</surname>
            <given-names>Kalyan
C.</given-names>
          </name>
          <xref rid="notes-1" ref-type="notes">#</xref>
        </contrib>
        <contrib contrib-type="author" id="ath2">
          <name>
            <surname>Ithychanda</surname>
            <given-names>Sujay S.</given-names>
          </name>
          <xref rid="notes-1" ref-type="notes">#</xref>
        </contrib>
        <contrib contrib-type="author" id="ath3">
          <name>
            <surname>Mohan</surname>
            <given-names>Maradumane L.</given-names>
          </name>
          <xref rid="notes-1" ref-type="notes">#</xref>
        </contrib>
        <contrib contrib-type="author" id="ath4">
          <name>
            <surname>Naga Prasad</surname>
            <given-names>Sathyamangla V.</given-names>
          </name>
        </contrib>
        <contrib contrib-type="author" corresp="yes" id="ath5">
          <name>
            <surname>Qin</surname>
            <given-names>Jun</given-names>
          </name>
          <xref rid="cor2" ref-type="other">*</xref>
        </contrib>
        <contrib contrib-type="author" corresp="yes" id="ath6">
          <name>
            <surname>Karnik</surname>
            <given-names>Sadashiva S.</given-names>
          </name>
          <xref rid="cor1" ref-type="other">*</xref>
        </contrib>
        <aff id="aff1">Department of Molecular Cardiology,
Lerner Research Institute, <institution>Cleveland Clinic</institution>, Cleveland, Ohio 44195, <country>United States</country></aff>
      </contrib-group>
      <author-notes>
        <corresp id="cor1"><label>*</label>NB50-76, Lerner Research Institute,
Cleveland Clinic, 9500 Euclid Ave., Cleveland, OH 44195. E-mail: <email>karniks@ccf.org</email>. Telephone: <phone>216-444-1269</phone>.
Fax: <fax>216-444-9263</fax>.</corresp>
        <corresp id="cor2"><label>*</label>E-mail: <email>qinj@ccf.org</email>.</corresp>
      </author-notes>
      <pub-date pub-type="epub">
        <day>13</day>
        <month>10</month>
        <year>2015</year>
      </pub-date>
      <pub-date pub-type="ppub">
        <day>10</day>
        <month>11</month>
        <year>2015</year>
      </pub-date>
      <volume>54</volume>
      <issue>44</issue>
      <fpage>6673</fpage>
      <lpage>6683</lpage>
      <history>
        <date date-type="received">
          <day>03</day>
          <month>09</month>
          <year>2015</year>
        </date>
        <date date-type="rev-recd">
          <day>13</day>
          <month>10</month>
          <year>2015</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>Copyright Â© 2015 American Chemical Society</copyright-statement>
        <copyright-year>2015</copyright-year>
        <copyright-holder>American Chemical Society</copyright-holder>
        <license license-type="editor-choice">
          <license-p>This is an open access article published under an ACS AuthorChoice <ext-link ext-link-type="uri" xlink:href="http://pubs.acs.org/page/policy/authorchoice_termsofuse.html">License</ext-link>, which permits copying and redistribution of the article or any adaptations for non-commercial purposes.</license-p>
        </license>
      </permissions>
      <abstract>
        <p content-type="toc-graphic">
          <graphic xlink:href="bi-2015-00975p_0009" id="ab-tgr1"/>
        </p>
        <p>Although
interaction of a few G protein-coupled receptors (GPCRs)
with Filamin A, a key actin cross-linking and biomechanical signal
transducer protein, has been observed, a comprehensive structureâfunction
analysis of this interaction is lacking. Through a systematic sequence-based
analysis, we found that a conserved filamin binding motif is present
in the cytoplasmic domains of &gt;20% of the 824 GPCRs encoded in
the
human genome. Direct high-affinity interaction of filamin binding
motif peptides of select GPCRs with the Ig domain of Filamin A was
confirmed by nuclear magnetic resonance spectroscopy and isothermal
titration calorimetric experiments. Engagement of the filamin binding
motif with the Filamin A Ig domain induced the phosphorylation of
filamin by protein kinase A in vitro. In transfected cells, agonist
activation as well as constitutive activation of representative GPCRs
dramatically elicited recruitment and phosphorylation of cellular
Filamin A, a phenomenon long known to be crucial for regulating the
structure and dynamics of the cytoskeleton. Our data suggest a molecular
mechanism for direct GPCRâcytoskeleton coupling via filamin.
Until now, GPCR signaling to the cytoskeleton was predominantly thought
to be indirect, through canonical G protein-mediated signaling cascades
involving GTPases, adenylyl cyclases, phospholipases, ion channels,
and protein kinases. We propose that the GPCR-induced filamin phosphorylation
pathway is a conserved, novel biochemical signaling paradigm.</p>
      </abstract>
      <custom-meta-group>
        <custom-meta>
          <meta-name>document-id-old-9</meta-name>
          <meta-value>bi5b00975</meta-value>
        </custom-meta>
        <custom-meta>
          <meta-name>document-id-new-14</meta-name>
          <meta-value>bi-2015-00975p</meta-value>
        </custom-meta>
        <custom-meta>
          <meta-name>ccc-price</meta-name>
          <meta-value/>
        </custom-meta>
      </custom-meta-group>
    </article-meta>
  </front>
  <body>
    <p id="sec1">G protein-coupled receptors (GPCRs) initiate wide-ranging responses,
including integrin-regulated processes such as cell migration, cell
survival, growth, chemotaxis, and the associated cell morphological
changes such as membrane ruffling, formation of filopodia, focal adhesions,
and formation of lamellipodia.<sup><xref ref-type="bibr" rid="ref1">1</xref>,<xref ref-type="bibr" rid="ref2">2</xref></sup> These fundamental changes
in cells are contingent upon engaging cytoskeletal proteins upon activating
the conventional G protein-dependent and -independent signaling mechanisms
involving proteins such as Î²-arrestin, small GTPases, and PDZ-containing
proteins.<sup><xref ref-type="bibr" rid="ref3">3</xref></sup> At a molecular level, cell morphological
changes or cytoskeletal responses to GPCRs are thought to be an indirect
outcome of signaling cascades, and as a consequence, direct binding
and activation of a major cytoskeletal protein by GPCRs are not considered
a mechanism at present. Biophysical and biochemical studies presented
here indicate that a substantial number of GPCRs may directly bind
and activate a major actin cross-linking protein, Filamin A (FLNa),
and that the binding triggers filamin phosphorylation by cellular
protein kinases.</p>
    <p>The relationship between GPCRs and cytoskeletal
modulation of cellular
phenotype is widely evident in physiological and pathological paradigms.
Apart from their well-established role as transducers of neuro-endocrine
hormone and sensory signals,<sup><xref ref-type="bibr" rid="ref4">4</xref></sup> GPCRs are
expressed at high levels in some breast,<sup><xref ref-type="bibr" rid="ref5">5</xref></sup> gynecological,<sup><xref ref-type="bibr" rid="ref6">6</xref></sup> neurological,<sup><xref ref-type="bibr" rid="ref7">7</xref></sup> and prostate cancers<sup><xref ref-type="bibr" rid="ref8">8</xref></sup> and alter invasive properties of tumor cells.<sup><xref ref-type="bibr" rid="ref9">9</xref></sup> Indeed, GPCR blockade is currently being explored as a
cancer therapy, and a majority of drugs used in clinical practice
are ligands for GPCRs.<sup><xref ref-type="bibr" rid="ref9">9</xref></sup> Antipsychotic drugs
target reorganization of nerve cytoskeletal components, which is critical
for neuronal morphology, plasticity, and the synaptic architecture
in the adult brain, via GPCR antagonism.<sup><xref ref-type="bibr" rid="ref10">10</xref></sup> However, definitive mechanisms for direct communication between
GPCRs and the cytoskeleton remain undefined.</p>
    <p>Filamin is an actin
binding dimeric cytoskeletal protein with 24
immunoglobulin (Ig) repeats that engages the cytoplasmic regions of
many transmembrane proteins.<sup><xref ref-type="bibr" rid="ref11">11</xref>,<xref ref-type="bibr" rid="ref12">12</xref></sup> A few genetic and biochemical
studies have reported interaction of GPCRs with FLNa. In these studies,
the role of FLNa in augmenting the membrane expression, subcellular
localization, trafficking, and signaling of GPCRs is emphasized. For
example, intracellular loop 3 (ICL3) of D2 and D3 dopamine receptors
was shown to interact with immunoglobulin-like repeat (Ig) 19 of FLNa
to promote proper cell surface expression and signaling.<sup><xref ref-type="bibr" rid="ref13">13</xref>â<xref ref-type="bibr" rid="ref15">15</xref></sup> The C-terminal tail (Ct) of the calcitonin receptor and CâC
chemokine receptor type 2 were shown to interact with FLNa Ig20â21
and Ig21â24, respectively, and play key roles in endocytic
sorting and internalization of the receptor.<sup><xref ref-type="bibr" rid="ref16">16</xref>,<xref ref-type="bibr" rid="ref17">17</xref></sup> Similarly, the interactions of the Î¼-type opioid receptor
with FLNa Ig24,<sup><xref ref-type="bibr" rid="ref18">18</xref>â<xref ref-type="bibr" rid="ref20">20</xref></sup> the calcium-sensing receptor with FLNa Ig14â15,<sup><xref ref-type="bibr" rid="ref21">21</xref>â<xref ref-type="bibr" rid="ref26">26</xref></sup> metabotropic glutamate receptor subtype 7b with FLNa Ig21â22,
and somatostatin receptor type 2 with FLNa Ig19â20 are reported
to play scaffolding and functional roles in GPCR signaling.<sup><xref ref-type="bibr" rid="ref27">27</xref>â<xref ref-type="bibr" rid="ref30">30</xref></sup> Filamin is a key mediator of epithelial defense against intrusion
of transformed cells;<sup><xref ref-type="bibr" rid="ref31">31</xref></sup> therefore, GPCR
signal regulation through FLNa is an important unexplored mechanism.</p>
    <p>FLNa Ig4, Ig9, Ig12, Ig17, Ig19, Ig21, and Ig23 are class A repeats
that possess a conserved binding site capable of engaging several
proteins such as platelet glycoprotein Ib Î± (GPIbÎ±), integrins,
and migfilin.<sup><xref ref-type="bibr" rid="ref32">32</xref></sup> Recently, these repeats
have been shown to reduce the level of integrin activation when overexpressed
in a platelet integrin model through a two-site binding mechanism.<sup><xref ref-type="bibr" rid="ref33">33</xref></sup> Among the class A repeats, Ig21 was shown to
have the highest binding affinity for the filamin ligands.<sup><xref ref-type="bibr" rid="ref32">32</xref></sup> Interestingly, Ig21 exists in an autoinhibited
form by engaging the N-terminal portion of the Ig20 repeat as an intramolecular
inhibitory ligand.<sup><xref ref-type="bibr" rid="ref34">34</xref></sup> Recruitment of filamin
binding proteins such as integrins and migfilin to filamin relieves
this autoinhibition and promotes structural reorganization of filamin.<sup><xref ref-type="bibr" rid="ref35">35</xref></sup> Recently, it has been revealed that disrupting
the Ig21 autoinhibition by FLNa ligands promoted protein kinase A
(PKA)-dependent phosphorylation of the S2152 site<sup><xref ref-type="bibr" rid="ref36">36</xref>,<xref ref-type="bibr" rid="ref37">37</xref></sup> on Ig20. Ligand-dependent S2152 phosphorylation by a variety of
FLNa ligands may be a novel pathway for activating filamin function
in diverse filamin-mediated cellular processes.</p>
    <p>Overall, the
current scientific literature suggests the potential
involvement of GPCRs in the engagement of different FLNa Ig repeats
during a variety of biological responses. Nevertheless, the mechanisms
for direct communication between GPCRs and FLNa remain poorly defined
at the molecular level. In this study, we found that &gt;20% of human
GPCRs are endowed with a likely FLNa binding motif (FBM). We demonstrate
high-affinity physical interaction of predicted FBMs for three different
GPCRs with FLNa Ig21: (i) angiotensin II type 1 receptor (AT1R), a
prototypical agonist-activated GPCR with important roles in cardiovascular
physiology, (ii) proto-oncogene MAS, a constitutively active GPCR
with a cardio-protective role, and (iii) Î±<sub>1D</sub>-adrenoreceptor
(Î±<sub>1D</sub>-AR), a neuro-hormone GPCR with cardiovascular
roles. As a consequence of high-affinity binding, we demonstrate enhanced
PKA-mediated filamin phosphorylation of Ig16â24 in vitro. We
further determined that GPCRs, AT1R, and MAS directly recruited FLNa
and promoted its phosphorylation by cellular S/T kinases in an agonist-dependent
manner. Our studies thus provide a structural framework for filamin
in GPCR signaling, potentially regulating a variety of cellular responses.</p>
    <sec id="sec2">
      <title>Experimental
Procedures</title>
      <sec id="sec2.1">
        <title>Peptides and Reagents</title>
        <p>The following peptides were synthesized
by the Biotechnology Core at the Lerner Research Institute of the
Cleveland Clinic: (1) D3R, VRKLSNGRLSTSLKLGPLQPRGV;
(2) MAS, KKKRFKESLKVVLTRAFK;
(3) AT1R, LGKKFKRYFLQLLKYIPPKA;
and (4) Î±<sub>1D</sub>-AR, KGHTFRSSLSVRLLKFSR.
All peptides were purified via high-performance liquid chromatography
and were &gt;95% pure. Peptide concentrations were estimated using
their
predicted extinction coefficient at <italic>A</italic><sub>280</sub> using the protein parameters tool on the ExPASY server (<uri xlink:href="http://web.expasy.org/pro/">http://web.expasy.org/pro/</uri>). In cases where the peptide did not have a UV signature, the thoroughly
lyophilized peptide was weighed carefully and an 85% purity was assumed
to estimate concentration.</p>
        <p>Human Filamin A (Uniprot entry P21333)
immunoglobulin domains Ig16â24 (1772â2647), Ig19 and
Ig21 were cloned into pGST-parallel vectors and purified as described
previously.<sup><xref ref-type="bibr" rid="ref32">32</xref>,<xref ref-type="bibr" rid="ref35">35</xref></sup> Phospho-Filamin A (S2152, #4761)
and Filamin A (#4762) polyclonal antibodies were obtained from Cell
Signaling Technology (Danvers, MA), while the antibody for GAPDH was
obtained from Life Technologies (Grand Island, NY). Filamin A monoclonal
antibody for detecting immunoprecipitated filamin was from Millipore
(MAB1680). Agonist peptide angiotensin II (AngII) for stimulation
was purchased from Bachem, and AT1R antagonist candesartan was a gift
from AstraZeneca. Specific MAS activating and inhibiting ligands AR234960
(AR-<italic>agonist</italic>) and AR244555 (AR-<italic>inverse</italic>), respectively, were unrestricted gifts from Arena Pharmaceuticals,
Inc. (San Diego, CA). PKA inhibitor H-89 was purchased from Sigma-Aldrich
(St. Louis, MO). MAS ligands and other inhibitors were dissolved in
dimethyl sulfoxide as 10 mM stocks. The pH of the buffer in the experiments
was verified to be neutral (7â7.5) after the ligands had been
added to the desired concentrations of 10â50 Î¼M.</p>
      </sec>
      <sec id="sec2.2">
        <title>Identifying
the Filamin Class A Repeat Binding Motif (FBM) in
GPCRs</title>
        <p>On the basis of the sequence alignment of peptides
from peptide-bound filamin structures [Protein Data Bank (PDB) entries 2BRQ, 2J3S, 2K9U, 2W0P, 2BP3, 2JF1, and 3ISW], homologous sequences,
and the predicted alignment of peptides from a previous study,<sup><xref ref-type="bibr" rid="ref38">38</xref></sup> we rationally defined the FBM as [X<sub>âa</sub>/R/K]<sub>â3</sub>-[Xâ²<sub>âa</sub>/R/K]<sub>â2</sub>-[Î©/Î¦/T]<sub>â1</sub>-[R/K/<underline>Î¦/S/F</underline>]<sub>0</sub>-[Î¶/E/D]<sub>1</sub>-Xâ²<sub>2</sub>-[Î¨/F]<sub>3</sub>-Xâ²<sub>4</sub>-[Î¨/R/K/Î©]<sub>5</sub>-Xâ²<sub>6</sub>-[Î¨/Î¦/Î©/M/R/K/S/P]<sub>7</sub>-X<sub>8</sub>, where Î¨ = L, V, I, or T, Î© = F,
W, or Y, Î¦ = A,V, I, or L, Î¶ = S, T, N, or Q, X represents
any amino acid, X<sub>âa</sub> represents any amino acid except
acidic residues (D and E), and Xâ² represents any amino acid
except P. In the FBM, the position (denoted as subscripts) of the
most conserved residue is numbered â0â and usually contains
a basic residue (K or R). In addition, in migfilin and CFTR peptide-bound
filamin structures, we observed that the lack of basic residues at
position 0 (underlined residues) appears to be compensated at position
â2 or â3. The basic residues at these positions appear
to be important for interactions of the peptide with FLNa Ig21, which
has a complementary acidic patch. Therefore, in our search algorithm,
we introduced the following additional conditions for residues at
positions â2 and â3: (1) the presence of K or R is a
must in case they are absent at position 0, and (2) no acidic residue
(D or E) is allowed. Furthermore, at positions â2 through 6,
the residue P was avoided as it is not a preferred residue in a Î²-strand.
A curated list of G protein-coupled receptors (GPCRs) was downloaded
from the UniProt Knowledgebase.<sup><xref ref-type="bibr" rid="ref39">39</xref></sup> All 824
human GPCR sequences in this list were scanned for (i) the FBM without
any mismatches and (ii) a 100% overlap of FBM in the intracellular
halves of transmembrane helices, intracellular loops, and C-terminal
regions as annotated in the downloaded sequence files. The Ig21 structure
from 2J3S is
represented by the electrostatic potential on the surface calculated
using the program APBS<sup><xref ref-type="bibr" rid="ref40">40</xref></sup> and contoured
at Â±12kT/e.</p>
      </sec>
      <sec id="sec2.3">
        <title><italic>In Vitro</italic> Kinase Assays</title>
        <p>The kinase
assay reaction conditions included 50 mM Tris (pH 7.5), 10 mM MgCl<sub>2</sub>, 10 Î¼M FLNaIg16â24 as a substrate, and 10, 50,
or 200 Î¼M filamin binding peptides (to release autoinhibition),
and 500 Î¼M ATP. For each 100 Î¼L reaction, 1000 units of
murine PKA (from NEB) was used. Protein phosphorylation was detected
by Western blotting using the phospho-Filamin A antibody (see <xref rid="sec2.1" ref-type="other">Peptides and Reagents</xref>).</p>
      </sec>
      <sec id="sec2.4">
        <title>Nuclear Magnetic Resonance
(NMR) Spectroscopy</title>
        <p><sup>15</sup>N-labeled proteins Ig19 and
Ig21 were purified,<sup><xref ref-type="bibr" rid="ref32">32</xref></sup> and the HSQC spectra
were recorded in a Bruker
Avance 600 MHz spectrometer at 30 Â°C. Spectral processing and
analysis were conducted using nmrPipe and NMRView.<sup><xref ref-type="bibr" rid="ref41">41</xref></sup></p>
      </sec>
      <sec id="sec2.5">
        <title>Isothermal Titration Calorimetry (ITC)</title>
        <p>A MicroCal iTC200
calorimeter from GE Healthcare was used for determining ligand affinities
for FLNa Ig repeats. Purified proteins were extensively buffer exchanged
into 25 mM sodium phosphate (pH 6.4), 5 mM NaCl, and 1 mM DTT. Peptide
ligands were dissolved in the same buffer and estimated as described
earlier; 50 Î¼M protein in the sample cell was titrated against
1 mM peptide in the syringe at 30 Â°C in 1 Î¼L increments
at a stirring speed of 1000 rpm. The solubility of the Î±<sub>1D</sub>-AR peptide was limited, and hence, this peptide was at an
effective concentration of 0.4 mM in the syringe. Affinities were
determined by fitting the heat changes to a one-site binding model
using the associated Origin package.</p>
      </sec>
      <sec id="sec2.6">
        <title>Expression of FBM-Containing
GPCRs, AT1R, and MAS Constructs
and Cell Culture</title>
        <p>The cloning of wild-type (WT) MAS with an
N-terminal <italic>myc</italic> tag and establishment of tetracycline/doxycycline-inducible
stable cell lines in HEK293 cells were described previously (HEK-MAS).<sup><xref ref-type="bibr" rid="ref42">42</xref></sup> These stable cell lines were maintained in a
humidified incubator at 37 Â°C and 5% CO<sub>2</sub> and grown
in complete medium (DMEM) supplemented with fetal bovine serum (10%),
penicillin/streptomycin (100 units/mL), blasticidin (5 Î¼g/mL),
and hygromycin (300 Î¼g/mL). For experiments, the cells were
induced with complete medium containing doxycycline (100 ng/mL) for
26â28 h for the expression of MAS. Uninduced cells were used
as negative controls in the experiments. Expression and characterization
of HA-tagged rat AT1R (HA-AT1R) in the HEK293 cell line were described
previously (HEK-AT1R).<sup><xref ref-type="bibr" rid="ref43">43</xref></sup></p>
      </sec>
      <sec id="sec2.7">
        <title>Co-immunoprecipitation
of Filamin with FBM-Containing GPCRs</title>
        <p>HEK293 and HEK-AT1R
cells were used for these experiments. For
the filaminâGPCR interaction experiment, HEK293 and HEK-AT1R
cells were serum starved for 4 h. The cells were lysed in Triton X-100
lysis buffer [0.8% Triton X-100, 20 mM Tris-HCl (pH 7.4), 300 mM NaCl,
1 mM EDTA, 20% glycerol, 0.1 mM PMSF, and leupeptin and aprotinin
at 10 Î¼g mL<sup>â1</sup> each]; 2 mg of total protein
was used to immunoprecipitate AT1R using the anti-HA affinity matrix
(Roche). Immunoprecipitates were resolved using 8% sodium dodecyl
sulfateâpolyacrylamide gel electrophoresis (SDSâPAGE)
and immunoblotted for filamin using anti-Filamin A monoclonal antibody
MAB1680 (Millipore). Blots were stripped and reblotted for HA to confirm
immunoprecipitation of HA-AT1R.</p>
      </sec>
      <sec id="sec2.8">
        <title>Evaluating Filamin Phosphorylation
Levels in Cells Expressing
FBM-Containing GPCRs</title>
        <p>HEK-AT1R and HEK-MAS cells were used
for these experiments. For the analysis of filamin phosphorylation,
HEK-AT1R cells were grown until they reached 80â90% confluency.
The cells were serum starved for 2 h and were pretreated with either
vehicle or AT1R antagonist candesartan (10 Î¼M) for 30 min. Following
this, AT1R-expressing cells were treated with either vehicle or agonist
angiotensin II (1 Î¼M) for 1 h. Whole cell protein lysates were
prepared from these cells in Mammalian Protein Extraction Reagent
buffer (M-PER from Thermo Scientific, Rockford, IL) with protease
and phosphatase inhibitors. Equal quantities (â¼25 Î¼g)
of these lysates were separated via 4 to 12% SDSâPAGE and then
transferred onto a nitrocellulose membrane for Western blot analysis.
The membranes were probed with pFLNa, FLNa, and GAPDH antibodies and
suitable near-infrared (IR) dye-conjugated secondary antibodies (LI-COR,
Lincoln, NE). The ratios of phospho-FLNa (pFLNa) to FLNa were calculated
on the basis of the fluorescence values and expressed as fold increase
over uninduced/untreated controls. GAPDH was used as an additional
control to confirm equivalent total protein loaded in the lanes. Data
for AT1R are presented as an average [mean Â± standard error of
the mean (SEM)] of two independent experiments (<italic>N</italic> = 2). Significance levels of an unpaired Studentâs <italic>t</italic> test are <italic>p</italic> &lt; 0.05. The HEK-MAS cells
were induced for 24 h with or without 10 Î¼M AR-<italic>inverse
agonist</italic>. This was followed by serum starvation of cells for
2 h without any inhibitors or with a combination of 10 Î¼M AR-<italic>inverse agonist</italic> or 10 Î¼M PKA-inhibitor (H-89) depending
on the experimental design. During induction and serum starvation,
AR-<italic>inverse agonist</italic> was added to the HEK-MAS cells
to prevent constitutive activation of MAS. Following serum starvation
and pretreatment with inhibitors, the cells were treated with 10 Î¼M
AR-<italic>agonist</italic> along with PKA inhibitor H-89 for 1 h.
FLNa phosphorylation in whole cell protein lysates was assayed on
Western blots as described for HEK-AT1R. Data for MAS are presented
as an average (mean Â± SEM) of three independent experiments (<italic>N</italic> = 3). Significance levels of an unpaired Studentâs <italic>t</italic> test are <italic>p</italic> &lt; 0.05.</p>
      </sec>
    </sec>
    <sec id="sec3">
      <title>Results</title>
      <sec id="sec3.1">
        <title>Frequency of
FBMs in GPCRs</title>
        <p>In a recent study,<sup><xref ref-type="bibr" rid="ref37">37</xref></sup> we recognized that filamin ligand peptides from
integrins and migfilin enhance PKA-mediated phosphorylation of S2152
in filamin by relieving autoinhibition of the Ig21 repeat by Ig20.
Because some GPCRs are known to interact with filamin,<sup><xref ref-type="bibr" rid="ref13">13</xref>â<xref ref-type="bibr" rid="ref15">15</xref></sup> we parsed the literature for GPCR-derived peptides that were reported
to bind filamin. The D3 dopamine receptor (D3R) peptide from the ICL3
region was shown to bind Ig19 of filamin. Many such peptides derived
from cell adhesion-related proteins bind class A Ig repeats of filamin
as reported previously.<sup><xref ref-type="bibr" rid="ref32">32</xref></sup> Similar to these
peptides, the D3R peptide increased the rate of PKA-mediated phosphorylation
at S2152 in the purified 100 kDa FLNa Ig16â24, a filamin surrogate,
as described previously<sup><xref ref-type="bibr" rid="ref36">36</xref>,<xref ref-type="bibr" rid="ref37">37</xref></sup> (<xref rid="fig1" ref-type="fig">Figure <xref rid="fig1" ref-type="fig">1</xref></xref>A). The effect though was not as pronounced
as those of strong binding migfilin, integrin Î²7, and GP1bÎ±-derived
peptides.<sup><xref ref-type="bibr" rid="ref37">37</xref></sup> The stronger ligands relieve
autoinhibition more effectively, thereby enhancing S2152 phosphorylation
by PKA. The result suggested that D3R not only binds to Ig19 but also
may bind to Ig21.<sup><xref ref-type="bibr" rid="ref32">32</xref></sup> We confirmed that this
ICL3 peptide from D3 dopamine receptor (D3R) binds FLNa Ig19 and Ig21
(<xref rid="fig1" ref-type="fig">Figure <xref rid="fig1" ref-type="fig">1</xref></xref>B,C) just
as other filamin binding peptides by HSQC NMR spectroscopy. The affinity
of the D3R peptide for Ig21 could not be assessed accurately by ITC
because of its lower affinity. However, this observation led us to
explore the possibility that the presence of FBM sequence in GPCRs
might be a conserved feature essential for directly engaging filamin
in cells and activating FLNa phosphorylation. We therefore used sequence
and structural information about known binders for the class A Ig
domain of FLNa including D3R and defined a consensus FBM for GPCRs
(see <xref rid="sec2" ref-type="other">Experimental Procedures</xref> and <xref rid="fig2" ref-type="fig">Figure <xref rid="fig2" ref-type="fig">2</xref></xref>). A bioinformatics
screening of the sequences of 824 human GPCRs uncovered conservation
of FBMs in the cytoplasmic regions of 116 nonolfactory GPCRs (<ext-link ext-link-type="uri" xlink:href="http://pubs.acs.org/doi/suppl/10.1021/acs.biochem.5b00975/suppl_file/bi5b00975_si_001.pdf">Table S1</ext-link>) and 73 olfactory GPCRs (<ext-link ext-link-type="uri" xlink:href="http://pubs.acs.org/doi/suppl/10.1021/acs.biochem.5b00975/suppl_file/bi5b00975_si_001.pdf">Table S2</ext-link>). Of particular significance to the
cell biological function of GPCRs is the finding that FBMs were predominantly
located in the functionally significant regions of GPCRs, the cytoplasmic
tail (Ct) followed by intracellular loop 3 (ICL3). Several novel candidate
GPCRs that can potentially engage FLNa with high affinity were found
in our search.</p>
        <fig id="fig1" position="float">
          <label>Figure 1</label>
          <caption>
            <p>Filamin binding D3 dopamine receptor peptide increases
the level
of PKA-mediated filamin phosphorylation and binds class A Ig repeats.
(A) Time-dependent phosphorylation of the 100 kDa band of FLNa Ig16â24
in the free form (lanes 1â4) and with 200 Î¼M dopamine
receptor 3 peptide (lanes 5â8). (B and C) HSQC spectra of FLNa
Ig19 and Ig21 in the free form (black) and in the presence of a 2-fold
excess of dopamine receptor peptide (red) showing that both these
repeats bind the peptide.</p>
          </caption>
          <graphic xlink:href="bi-2015-00975p_0002" id="gr1" position="float"/>
        </fig>
        <fig id="fig2" position="float">
          <label>Figure 2</label>
          <caption>
            <p>Sequence and structural analysis of FLNa binding motifs. (A) Sequence
alignment of known FLNa ligands. The peptide ligands are derived from
various sources. A dagger denotes X-ray structures (chain annotation).
A section mark denotes NMR structure. Double daggers denote homologous
sequences of integrin Î²1 and integrin Î²3, and predicted
alignment of dopamine receptor peptides from a previous study.<sup><xref ref-type="bibr" rid="ref37">37</xref></sup> Basic residues are colored blue, acidic residues
red, uncharged polar residues green, and hydrophobic residues black.
The most conserved residue position is designated 0, and all residues
are labeled accordingly (numbering above the alignment). The cartoon
of the Î²-sheet on the top of the alignment depicts the secondary
structure adopted by the FLNa ligand in the PDB structures. The residues
that are important for defining the FLNa binding motif (FBM) are also
highlighted with shading. (B) Overlay of FLNa ligands on FLNA Ig21
upon structural alignment of Ig21 and Ig17 from different PDB structures
(2BRQ, 2J3S, 2W0P, 2BP3, 2JF1, and 3ISW). The Ig21 structure
from 2J3S is
represented by the electrostatic potential on the surface calculated
using the program APBS<sup><xref ref-type="bibr" rid="ref40">40</xref></sup> and contoured
at Â±12kT/e. Acidic and basic charged surface areas are colored
red and blue, respectively. The internal FBM peptide from Ig20 (2J3S)
is shown as a cartoon and colored cyan. The FBMs from integrin Î²7,
integrin Î²2, migfilin, CFTR, and GPIbÎ± are shown as sticks.
The acidic patch on Ig21 and the complementary basic residues of the
FBMs are circled. The N-terminus of the bound peptide (cyan) is in
the circled part (left side of the protein), and the C-terminal end
of the bound peptide (cyan) is sticking out of the Ig repeat on the
right side of the Ig repeat.</p>
          </caption>
          <graphic xlink:href="bi-2015-00975p_0003" id="gr2" position="float"/>
        </fig>
        <p>We selected AT1R and MAS from this list for experimental
verification
given their importance in cardiovascular physiology. The FBM in AT1R
and MAS is present in the Ct. In the recently determined structure
of AT1R,<sup><xref ref-type="bibr" rid="ref44">44</xref></sup> the position of FBM overlaps
with the functionally important and structurally flexible âhelix
8â region. The Î±<sub>1D</sub>-adrenoreceptor (Î±<sub>1D</sub>-AR) with cardiovascular and neuronal roles was chosen as
a representative GPCR with the predicted FBM in ICL3.<sup><xref ref-type="bibr" rid="ref45">45</xref>,<xref ref-type="bibr" rid="ref46">46</xref></sup> The ICL3 loop is a very important determinant for G protein activation
by GPCRs. To the best of our knowledge, there have been no studies
reporting the direct interaction of these three GPCRs with FLNa.</p>
      </sec>
      <sec id="sec3.2">
        <title>FLNa Ig 21 Binds to Predicted FBMs from AT1R, MAS, and Î±<sub>1D</sub>-AR</title>
        <p>FLNa Ig21 is the representative filamin Ig repeat
used extensively to test ligand binding.<sup><xref ref-type="bibr" rid="ref32">32</xref>,<xref ref-type="bibr" rid="ref35">35</xref></sup> We therefore performed NMR spectroscopy and ITC experiments on the
binding of this repeat with the GPCR-derived FBM peptides. Binding
of all three FBM peptides to Ig21 resulted in significant changes
in the <sup>15</sup>N HSQC spectra (<xref rid="fig3" ref-type="fig">Figure <xref rid="fig3" ref-type="fig">3</xref></xref>A,C,E). In the spectra, peaks for G2267,
G2270, and S2279 that occupy the top and bottom of the âCDâ
ligand binding groove showed changes that are typical of high-affinity
binders.<sup><xref ref-type="bibr" rid="ref32">32</xref>,<xref ref-type="bibr" rid="ref36">36</xref></sup> Hence, these peptides most likely bind in
a mode similar to that of the known filamin Igâpeptide complex
structures through a Î²-strand augmentation. ITC experiments
estimated the binding affinities of peptide motifs of AT1R, MAS, and
Î±<sub>1D</sub>-AR for FLNa Ig21 with <italic>K</italic><sub>d</sub> values of 0.8, 0.3, and 0.8 Î¼M, respectively. These
binding affinities are 50â100 times higher than those of the
FBM peptides from cell adhesion proteins, the integrins, which are
the most common filamin binding proteins in a majority of cell types
(see <xref rid="sec4" ref-type="other">Discussion</xref>). The Î²7 integrin Ct
peptide binds Ig21 with a <italic>K</italic><sub>d</sub> of 40 Î¼M.<sup><xref ref-type="bibr" rid="ref47">47</xref></sup> These binding affinities are among the tightest
known to bind filamin with the exception of the platelet specific
protein, GPIbÎ±,<sup><xref ref-type="bibr" rid="ref32">32</xref></sup> which has an affinity
of 0.1 Î¼M.</p>
        <fig id="fig3" position="float">
          <label>Figure 3</label>
          <caption>
            <p>Interaction of AT1R, MAS, and Î±<sub>1D</sub>-AR
FBMs with
FLNa Ig21. HSQC spectra of the <sup>15</sup>N-labeled FLNa Ig21 repeat
with (A) AT1R, (C) MAS, and (E) Î±<sub>1D</sub>-AR peptides show
extensive spectral changes indicating a strong binding event. The
peptides used in the experiments are also shown with the residues
colored as described in the legend of <xref rid="fig2" ref-type="fig">Figure <xref rid="fig2" ref-type="fig">2</xref></xref>. (B, D, and F) Corresponding ITC measurements
with calculated binding affinities are shown. These affinities are
tighter than those of any know GPCR peptide and protein partners determined
by isothermal calorimetry. The Î±<sub>1D</sub>-AR peptide was
at a concentration of 0.4 mM in the syringe, unlike the concentration
of 1 mM for AT1R and MAS, and hence, the slope of the titration is
different, though the affinities are comparable.</p>
          </caption>
          <graphic xlink:href="bi-2015-00975p_0004" id="gr3" position="float"/>
        </fig>
        <p>Given that the filaminâadhesion receptor FBM interaction
is tightly coupled to filamin phosphorylation at S2152 by PKA,<sup><xref ref-type="bibr" rid="ref37">37</xref></sup> we tested the effect of these GPCR FBM peptides
on FLNa phosphorylation at S2152 in the filamin surrogate, FLNa Ig16â24,
by PKA in an <italic>in vitro</italic> kinase assay. As expected,
binding of these FBM peptides enhanced the rate of phosphorylation
of the 100 kDa surrogate of FLNa at S2152 by PKA in vitro (<xref rid="fig4" ref-type="fig">Figure <xref rid="fig4" ref-type="fig">4</xref></xref>) like the conventionally
known FLNa ligands, integrins, and migfilin.<sup><xref ref-type="bibr" rid="ref32">32</xref></sup> This enhancement of filamin S2152 phosphorylation by high-affinity
FBM peptides derived from AT1R, MAS, and Î±<sub>1D</sub>-AR was
much more robust than that of the D3R-derived peptide that binds with
a lower affinity (<xref rid="fig1" ref-type="fig">Figure <xref rid="fig1" ref-type="fig">1</xref></xref>A vs <xref rid="fig4" ref-type="fig">Figure <xref rid="fig4" ref-type="fig">4</xref></xref>). This observation further emphasizes our premise that tighter binding
ligands drive the filamin Ig21 domain conformation toward a PKA compliant
state.<sup><xref ref-type="bibr" rid="ref32">32</xref></sup> These findings validate the finding
that the predicted FBMs in GPCRs are bona fide functional units and
therefore may confer the ability to recruit FLNa to agonist-activated
GPCRs in cells.</p>
        <fig id="fig4" position="float">
          <label>Figure 4</label>
          <caption>
            <p>Time-dependent phosphorylation of FLNa Ig16â24
(â¼100
kDa) in the absence (the first two lanes from the left in each blot)
and presence of FBMs (+,10 Î¼M; ++, 50 Î¼M; the two lanes
on the right in each blot) of AT1R (left), MAS (center), and Î±<sub>1D</sub>-AR (right).</p>
          </caption>
          <graphic xlink:href="bi-2015-00975p_0005" id="gr4" position="float"/>
        </fig>
      </sec>
      <sec id="sec3.3">
        <title>AT1R Binds to Filamin, and the Agonist Treatment of AT1R Promotes
Filamin Phosphorylation</title>
        <p>To demonstrate ligand regulation
of a native GPCR interaction with filamin in cells, we selected ATIR
as a model receptor. Immunoprecipitation of HA-tagged rat AT1R from
detergent-solubilized HEK-AT1R cell lysates using an anti-HA monoclonal
antibody showed co-immunoprecipitation of endogenous Filamin A (280
kDa) with HA-AT1R (â78 kDa). HEK cells not expressing HA-AT1R
were used as a negative control (<xref rid="fig5" ref-type="fig">Figure <xref rid="fig5" ref-type="fig">5</xref></xref>A). Immunoprecipitation of HA-tagged AT1R
is shown in the bottom panel (<xref rid="fig5" ref-type="fig">Figure <xref rid="fig5" ref-type="fig">5</xref></xref>A). We next examined whether ligand-modulated receptor
activity is associated with phosphorylation of filamin in cells. Treatment
of the cells with the agonist peptide AngII led to a 5-fold higher
level of filamin phosphorylation, and treatment with the inverse agonist,
candesartan, reduced the level of filamin phosphorylation to basal
levels (<xref rid="fig5" ref-type="fig">Figure <xref rid="fig5" ref-type="fig">5</xref></xref>B).
Together, these results demonstrate that endogenous Filamin A binds
AT1R and agonist activation of AT1R enhances phosphorylation of cellular
filamin at S2152, suggesting a direct role for AT1R in actin remodeling
through filamin.</p>
        <fig id="fig5" position="float">
          <label>Figure 5</label>
          <caption>
            <p>Physical and functional interactions of full-length AT1R
with FLNa.
(A) AngII receptor AT1R complexes with filamin (280 kDa) in HEK cells.
(B) AT1R-mediated FLNa phosphorylation upon stimulation with AngII
and the lack of FLNa phosphorylation when treated with the antagonist
candesartan. The data represent two independent (<italic>N</italic> = 2) experiments.</p>
          </caption>
          <graphic xlink:href="bi-2015-00975p_0006" id="gr5" position="float"/>
        </fig>
      </sec>
      <sec id="sec3.4">
        <title>Physical and Functional
Interaction of MAS with FLNa</title>
        <p>We studied MAS to substantiate
GPCR-linked filamin phosphorylation
results, as MAS is a constitutively active oncogenic GPCR with promiscuous
G protein coupling ability.<sup><xref ref-type="bibr" rid="ref42">42</xref></sup> In addition,
it contains a bona fide FBM that binds Ig21 with very high affinity
as measured by robust biophysical techniques (<xref rid="fig3" ref-type="fig">Figure <xref rid="fig3" ref-type="fig">3</xref></xref>C,D). For these studies, we used the tetracycline-inducible
system of myc-tagged human MAS expression in HEK293 cells as previously
described.<sup><xref ref-type="bibr" rid="ref42">42</xref></sup> We examined functional coupling
between MAS and endogenous FLNa in tetracycline-induced cells by monitoring
FLNa phosphorylation at S2152. The uninduced cells served as a control.
Tetracycline induction of MAS expression alone caused a 7-fold increase
in the level of phosphorylation of FLNa (<xref rid="fig6" ref-type="fig">Figure <xref rid="fig6" ref-type="fig">6</xref></xref>A). This is not surprising as we and others
have reported the high constitutive activity of MAS.<sup><xref ref-type="bibr" rid="ref42">42</xref>,<xref ref-type="bibr" rid="ref48">48</xref>,<xref ref-type="bibr" rid="ref49">49</xref></sup> FLNa phosphorylation induced
by the constitutive activity of MAS was abolished in cells treated
with a specific inhibitor of the constitutive activity of MAS, AR-<italic>inverse agonist</italic> (<xref rid="fig6" ref-type="fig">Figure <xref rid="fig6" ref-type="fig">6</xref></xref>B). Treatment of MAS-expressing cells with a specific
MAS agonist, AR-<italic>agonist</italic>, further increased the level
of phosphorylation of FLNa 10-fold (<xref rid="fig6" ref-type="fig">Figure <xref rid="fig6" ref-type="fig">6</xref></xref>A). Agonist stimulation of cells pretreated
with AR-<italic>inverse agonist</italic> (during induction) resulted
in a 9-fold increase in the level of FLNa phosphorylation (<xref rid="fig6" ref-type="fig">Figure <xref rid="fig6" ref-type="fig">6</xref></xref>B). Unlike AT1R,
MAS activates all major G proteins in cells, including the G<sub>s</sub> protein-coupled cAMP pathway leading to the activation of PKA. Consistent
with this finding, treatment of MAS agonist-activated cells with the
PKA inhibitor, H-89, resulted in reversal of the phosphorylated FLNa
(pFLNa) levels to constitutive levels (<xref rid="fig6" ref-type="fig">Figure <xref rid="fig6" ref-type="fig">6</xref></xref>A). Furthermore, treatment with H-89 decreased
the pFLNa levels by 60% in cells pretreated with AR-<italic>inverse
agonist.</italic> These experiments demonstrate that only a part of
FLNa phosphorylation in cells by both constitutive and agonist activation
of MAS is PKA-dependent. The remaining phosphorylation takes place
perhaps by other cellular Ser/Thr kinases.</p>
        <fig id="fig6" position="float">
          <label>Figure 6</label>
          <caption>
            <p>Functional interaction
of MAS with FLNa. (A) MAS-mediated FLNa
phosphorylation upon stimulation with AR-<italic>agonist</italic> and
its inhibition by PKA inhibitor H-89 in MAS-expressing [induced (IN)]
and control [uninduced (UI)] cells. (B) FLNa phosphorylation under
inhibition of constitutive activity. Inhibition of constitutive activation
of MAS by AR-<italic>inverse agonist</italic> (AR-<italic>inv</italic>) abolished constitutive FLNa phosphorylation. Under these conditions,
treatment with AR-<italic>agonist</italic> stimulated maximal FLNa
phosphorylation. PKA inhibitor H-89 partially inhibited AR-<italic>agonist</italic>-induced FLNa phosphorylation. Data are averages
(mean Â± SEM) of three independent experiments (<italic>N</italic> = 3).</p>
          </caption>
          <graphic xlink:href="bi-2015-00975p_0007" id="gr6" position="float"/>
        </fig>
        <p>Experiments depicted in <xref rid="fig5" ref-type="fig">Figures <xref rid="fig5" ref-type="fig">5</xref></xref> and <xref rid="fig6" ref-type="fig">6</xref> suggest that the FBM
in AT1R and MAS likely adopts a FLNa binding conformation only upon
receptor activation. AT1R does not signal constitutively and needs
agonist binding to activate the filamin binding mode; however, MAS
likely binds filamin constitutively and hence leads to constitutive
filamin phosphorylation. These results emphasize that it is the active
receptor that mediates filamin phosphorylation by PKA or other cellular
S/T kinases. Overall, our data suggest (i) conservation of FBM in
GPCRs and (ii) receptor activation-dependent phosphorylation of FLNa
that is most likely a consequence of FLNaâGPCR interactions.</p>
        <fig id="fig7" position="float">
          <label>Figure 7</label>
          <caption>
            <p>Model
for select GPCR-mediated Filamin A phosphorylation. The agonist-bound
receptor couples to filamin, thereby releasing autoinhibition of filamin,
and this in turn promotes PKA-mediated S2152 phosphorylation.</p>
          </caption>
          <graphic xlink:href="bi-2015-00975p_0008" id="gr7" position="float"/>
        </fig>
      </sec>
    </sec>
    <sec id="sec4">
      <title>Discussion</title>
      <p>Impetus
for (i) the bioinformatics discovery of FBM in &gt;20% of
GPCRs and (ii) experimental validation of GPCRs as bona fide ligands
for relieving the autoinhibited state of FLNa is based on our recently
reported findings.<sup><xref ref-type="bibr" rid="ref37">37</xref></sup> It was found that
phosphorylation of S2152 in filamin was dependent on relieving autoinhibition
of Ig20 by engagement of Ig21 by receptors harboring an FBM. Conventionally
studied filamin activators were peptides derived from cell adhesion
molecules. Migfilin, integrin Î²7, and GPIbÎ± peptides enhanced
PKA-mediated filamin phosphorylation <italic>in vitro</italic>, indicating
that functionally diverse ligands can promote filamin phosphorylation.
Regulation of the homeostatic equilibrium between FLNa and pFLNa by
these conventional activators is known to be critical in cell cytoskeletal
dynamics, leading to changes in cell adhesion responses.<sup><xref ref-type="bibr" rid="ref33">33</xref></sup> Though there is literature about filaminâGPCR
interaction at the functional and biochemical level, broad generalizations
were obscure at best. The D2R and D3R peptides were the most clearly
recognized class A filamin binders.<sup><xref ref-type="bibr" rid="ref38">38</xref>,<xref ref-type="bibr" rid="ref32">32</xref></sup> The extent
of the involvement of FBMs in GPCRs, the superfamily of cell surface
receptors for conducting FLNa-mediated cytoskeletal signaling, is
a major gap in the current knowledge base. To bridge this gap, we
report here for the first time a consensus FBM in GPCRs and identify
several GPCRs that contain FBMs in their intracellular regions. We
noticed several important GPCRs that are part of this select GPCR
list (<ext-link ext-link-type="uri" xlink:href="http://pubs.acs.org/doi/suppl/10.1021/acs.biochem.5b00975/suppl_file/bi5b00975_si_001.pdf">Table S1</ext-link>). For example, lysophosphatidic
acid treatment was reported to increase the level of FLNa phosphorylation
in previous studies.<sup><xref ref-type="bibr" rid="ref50">50</xref></sup> However, the role
of any particular receptor in the process was not addressed. Our predicted
hits contain lysophosphatidic acid receptor 2, suggesting a possible
role for this receptor in directly engaging FLNa. Similarly, kinin
treatment was shown to alter filamin translocation in endothelial
cells.<sup><xref ref-type="bibr" rid="ref51">51</xref>,<xref ref-type="bibr" rid="ref52">52</xref></sup> The roles of B1 and B2 bradykinin receptors
(B1R and B2R) were mentioned in this process, but never proven. In
our predictions, we identified B2R to contain the FBM, and most interestingly,
a pairwise sequence alignment between B1R and B2R reveals a gap in
the sequence of B1R at the homologous region spanning the entire length
of the FBM, thus providing evidence of the role of B2R but not B1R
in the process. Similar, differences in the FBM regions were seen
in neuropeptide FF receptors 1 and 2 and dopamine receptors.</p>
      <p>Along with the known filamin binders such as dopamine receptors,
we also identified several important GPCRs that respond to serotonin,
acetylcholine, opioids, angiotensin, chemokines, eicosanoids, and
fatty acid ligands. Our list also included the recently identified
CXCR4 FBM as a positive hit, although the FBM in this receptor spans
both the cytoplasmic and transmembrane regions. The list also has
several orphan, olfactory, and taste receptors. Few of the GPCRs that
were previously reported to interact with filamin are absent from
our list. This is expected as in this study we attempted to define
FBM for only class A repeats in FLNa with very strict criteria. We
speculate that via expansion of the definition of FBM to include proteins
binding to (1) repeats other than class A and (2) other filamin isoforms
(B and C), the predicted list of GPCRs for interacting with filamin
would be substantially large. More crystal structures of peptide motifs
with FLN Ig domains would further aid in improving these predictions.
Because our predictions are based on a limited number of crystal structures
with peptides, the potential for false positive hits as well as missing
more potent filamin binding GPCRs cannot be excluded. Our search criteria
were stringent, and all 12 residues needed for filamin engagement
were filtered to be part of cytoplasmic regions (see <xref rid="sec2" ref-type="other">Experimental Procedures</xref>).</p>
      <p>From the predicted list, we
picked three different GPCRs, MAS,
AT1R, and Î±<sub>1D</sub>-AR, which are important in cardiovascular
physiology, for further experimental validation. These three receptor
peptides have no known topological constraints with respect to binding
filamin. Using NMR and ITC, we show unambiguous tight binding of the
FBM peptides to FLNa Ig21. The affinities in the nanomolar range determined
by ITC are extremely rare for filamin binders. Only the platelet specific
GP1bÎ± receptor peptide shows a binding tighter than those of
the three GPCRs listed above.<sup><xref ref-type="bibr" rid="ref32">32</xref></sup> Compared
to integrins,<sup><xref ref-type="bibr" rid="ref47">47</xref></sup> the three GPCR peptides
tested here have 50â100-fold higher affinity and are likely
to be very biologically potent. We are not aware of any report of
GPCR peptides showing such high affinity by ITC for any known GPCR
binder. The only study we came across is the binding of the cannabinoid
receptor peptide to Î²-arrestin with an affinity of 2 Î¼M.<sup><xref ref-type="bibr" rid="ref54">54</xref></sup> Furthermore, the bound FBM peptides promoted
rapid phosphorylation of FLNa at S2152 under <italic>in vitro</italic> conditions, validating our biophysical studies.</p>
      <p>In strong
support of the <italic>in vitro</italic> findings that
ligand binding induces FLNa phosphorylation at S2152, we observed
robust phosphorylation of FLNa on the S2152 site in cells expressing
the FBM-containing GPCRs, AT1R and MAS. We note that unlike AT1R there
was strong basal/constitutive (agonist-independent) filamin phosphorylation
induced by MAS. This was expected as the cAMP levels are significantly
higher at basal levels in MAS-expressing cells,<sup><xref ref-type="bibr" rid="ref42">42</xref>,<xref ref-type="bibr" rid="ref48">48</xref></sup> causing PKA activation that could be inhibited by H-89. To tease
out acute or short-term signaling effects of MAS and its consequences
in cells, we inhibited constitutive activity by adding AR-<italic>inverse agonist</italic> to the cells at the time of induction. This
allowed us to demonstrate the receptor activation-dependent increase
in the level of phosphorylation of FLNa. The lack of robust reagents
prevented us from extending our results to Î±<sub>1D</sub>-AR.</p>
      <p>Intriguingly, only 60% of the increase in pFLNa in MAS-expressing
cells was inhibited by H-89, suggesting the involvement of kinases
other than PKA in the process.<sup><xref ref-type="bibr" rid="ref12">12</xref></sup> The residual
component of pFLNa is most likely generated by kinases that are activated
in the cells by other G protein pathways.<sup><xref ref-type="bibr" rid="ref50">50</xref>,<xref ref-type="bibr" rid="ref55">55</xref></sup> Constitutive or ligand-dependent activation of AT1R and MAS likely
introduces conformational changes in the FBM that is suitable for
FLNa engagement. Thereby, AT1R and MAS directly bind to Ig21 and prevent
autoinhibition of FLNa Ig21 by Ig20. The resultant GPCR-bound FLNa
becomes a substrate for kinases (not limited to PKA) that are active
in cells through signaling or independently by other mechanisms. Ser/Thr
kinase such as ribosomal S6 kinase activated upon AT1R activation
is a known FLNa phosphorylating kinase.<sup><xref ref-type="bibr" rid="ref50">50</xref>,<xref ref-type="bibr" rid="ref56">56</xref></sup> Overall, kinases
increase pFLNa levels in the cells and likely promote cytoskeletal
assembly. Taken together, these two receptors seem to couple with
filamin during or immediately after agonist activation. Antagonist
binding prevents phosphorylation of filamin with both of these receptors,
validating our agonist data. The details of this process most likely
involve a helix/loop to Î²-strand change in the Ct regions of
the receptors that transiently enhances filamin binding only in the
presence of the agonists. The cytoplasmic regions of GPCR also bind Î²-arrestin
following agonist activation. In a previous proteomic study, FLNa
was shown to interact with Î²-arrestin.<sup><xref ref-type="bibr" rid="ref57">57</xref></sup> Whether Î²-arrestin assembly plays a role in the interaction
of FLNa with GPCRs and subsequent FLNa phosphorylation is currently
unknown and is an interesting area for future research. The enhanced
engagement of filamin to an activated receptor is seen in some recent
work though not recognized as such.<sup><xref ref-type="bibr" rid="ref53">53</xref></sup> Our
model provides a molecular explanation of the previously reported
G protein signaling-mediated filamin phosphorylation in which direct
FLNaâGPCR interaction was not observed (Figure <xref rid="fig7" ref-type="fig">7</xref>).<sup><xref ref-type="bibr" rid="ref50">50</xref>,<xref ref-type="bibr" rid="ref58">58</xref></sup></p>
      <p>This is the first report
to demonstrate filamin phosphorylation
tied to the activation status of GPCRs. Filamin phosphorylation has
been linked to defects in neuronal migration, actin binding, and cytoplasmic
localization<sup><xref ref-type="bibr" rid="ref59">59</xref></sup> through guanine exchange
factor ARFGEF2. Interestingly, agonist-dependent filamin phosphorylation
appears not to be limited to G<sub>s</sub>-coupled GPCRs as observed
in this study and in other reports. This implies that a cAMP-independent
activation of PKA may play a role in case of those GPCRs. Evidence
of such a phenomenon is available for mouse AT1A and endothelin-1
receptors.<sup><xref ref-type="bibr" rid="ref60">60</xref></sup> Filamin phosphorylation might
reposition filamin with respect to the plasma membrane because of
charge repulsion, and in this new microenvironment, its binding partners
may change, thereby bridging a different set of proteins. Filamin
seems necessary for optimal coupling of G protein to D3R,<sup><xref ref-type="bibr" rid="ref14">14</xref></sup> and dopamine treatment has been shown to reduce
the extent of binding of filamin to the receptor.<sup><xref ref-type="bibr" rid="ref61">61</xref></sup> Filamin has been shown to form a complex with the Î²-arrestin
and GPCR in at least three cases, i.e., D3R,<sup><xref ref-type="bibr" rid="ref61">61</xref></sup> AT1R, and muscarinic M1 receptor (M1MR).<sup><xref ref-type="bibr" rid="ref62">62</xref></sup> The Ig22 domain of filamin was characterized as the most likely
docking site for Î²-arrestin, and a Î²-arrestinâFLNaâreceptor
complex regulates ERK activation and membrane ruffling.<sup><xref ref-type="bibr" rid="ref62">62</xref></sup> However, direct binding of filamin to the AT1R
and M1MR was not considered a mechanism in the previous work. However,
our bioinformatics search identified a potetnial FBM in M1MR (<ext-link ext-link-type="uri" xlink:href="http://pubs.acs.org/doi/suppl/10.1021/acs.biochem.5b00975/suppl_file/bi5b00975_si_001.pdf">Table S1</ext-link>). More structural information acquired
by NMR or crystallography will help in robust hypothesis generation
to unravel the precise molecular details. In AT1R and MAS, the FBM
is part of the cytoplasmic helix 8 that plays a crucial but imprecisely
defined role in various GPCRs.<sup><xref ref-type="bibr" rid="ref63">63</xref></sup> In AT1R
and other GPCRs, this region was also shown and/or predicted to bind
to tubulin.<sup><xref ref-type="bibr" rid="ref64">64</xref></sup> In most crystal structures
of GPCRs, this region is a helix, part of a helix, or unstructured
or has missing electron density (PDB entries 4DAJ, 2R4S, 3ODU, 3VW7, and 4YAY). We envisage an
agonist/antagonist-dependent conformational switch in this region
of many GPCRs that facilitate filamin engagement. Given our data,
the role that filamin and its phosphorylation plays in GPCR function
will have to be pursued with more vigor.</p>
      <p>On a final note, the
class A Ig repeats of filamin mainly bind
unstructured segments of membrane receptors. It is also interesting
to note that the cytoplasmic regions, especially the ICL3 and Ct regions
of GPCRs, are highly variable in length and are predicted to be intrinsically
disordered.<sup><xref ref-type="bibr" rid="ref65">65</xref>,<xref ref-type="bibr" rid="ref66">66</xref></sup> Given that &gt;30% of the eukaryotic
proteomes contains disordered segments,<sup><xref ref-type="bibr" rid="ref67">67</xref>â<xref ref-type="bibr" rid="ref69">69</xref></sup> it is tempting to speculate
that filamin may bind many more proteins than currently recognized.
Moreover, Filamin Ig repeats have expanded in number during eukaryotic
evolution,<sup><xref ref-type="bibr" rid="ref70">70</xref></sup> and this may have some correlation
with the expansion of disordered segments in many signaling proteins.
There is speculation in the literature that millions of such disordered
motifs may exist,<sup><xref ref-type="bibr" rid="ref71">71</xref></sup> and large proteins
like filamin with their ability to bind these motifs may have co-evolved.
FLNa is also alternately spliced, resulting in an isoform that lacks
autoinhibtion and the S2152 phosphorylation site.<sup><xref ref-type="bibr" rid="ref72">72</xref>,<xref ref-type="bibr" rid="ref73">73</xref></sup> Filamin isoform switching may therefore regulate both mechanistic
and signaling outcomes during animal development.</p>
    </sec>
  </body>
  <back>
    <notes id="notes-2" notes-type="si">
      <title>Supporting Information Available</title>
      <p>The Supporting Information
is available free of charge on the <ext-link ext-link-type="uri" xlink:href="http://pubs.acs.org">ACS Publications website</ext-link> at DOI: <ext-link ext-link-type="uri" xlink:href="http://pubs.acs.org/doi/abs/10.1021/acs.biochem.5b00975">10.1021/acs.biochem.5b00975</ext-link>.<list id="silist" list-type="simple"><list-item><p>A list of GPCRs
having predicted filamin binding motifs
(Tables S1 and S2) (<ext-link ext-link-type="uri" xlink:href="http://pubs.acs.org/doi/suppl/10.1021/acs.biochem.5b00975/suppl_file/bi5b00975_si_001.pdf">PDF</ext-link>)</p></list-item></list></p>
    </notes>
    <sec sec-type="supplementary-material">
      <title>Supplementary Material</title>
      <supplementary-material content-type="local-data" id="sifile1">
        <media xlink:href="bi5b00975_si_001.pdf">
          <caption>
            <p>bi5b00975_si_001.pdf</p>
          </caption>
        </media>
      </supplementary-material>
    </sec>
    <notes id="notes-1">
      <title>Author Contributions</title>
      <p><sup>#</sup> K.C.T., S.S.I., and M.L.M. are joint first authors.</p>
    </notes>
    <notes id="notes-44" notes-type="funding-statement">
      <p>This work is
supported by National Institutes of Health Grants HL057470 and HL089473
to S.S.K. and GM062823 to J.Q. M.L.M. was supported by an American
Heart Association scientist development grant (13SDG17110076).</p>
    </notes>
    <notes id="NOTES-d476e1000-autogenerated" notes-type="conflict-of-interest">
      <p>The
authors declare no
competing financial interest.</p>
    </notes>
    <ack>
      <title>Acknowledgments</title>
      <p>We thank Dr. Dianne Perez (Cleveland Clinic) for providing
rat fibroblasts stably transfected with human Î±<sub>1D</sub>-adrenoreceptor. We thank Dr. Mitali Das for advice on the use of
anti-filamin antibodies for immunoprecipitation experiments. We thank
Dr. Smarajit Bandyopadhyay and Weizhen Shen from the Molecular Biotechnology
Core at the Lerner Research Institute for peptide synthesis. We also
thank David Schumick from the Center for Medical Art and Photography
at the Cleveland Clinic for help with illustrations.</p>
    </ack>
    <glossary id="dl1">
      <def-list>
        <title>Abbreviations</title>
        <def-item>
          <term>GPCRs</term>
          <def>
            <p>G protein-coupled receptors</p>
          </def>
        </def-item>
        <def-item>
          <term>PKA</term>
          <def>
            <p>protein kinase
A</p>
          </def>
        </def-item>
        <def-item>
          <term>FLNa</term>
          <def>
            <p>Filamin A</p>
          </def>
        </def-item>
        <def-item>
          <term>Ig</term>
          <def>
            <p>immunoglobulin</p>
          </def>
        </def-item>
        <def-item>
          <term>AT1R</term>
          <def>
            <p>angiotensin II
type receptor I</p>
          </def>
        </def-item>
        <def-item>
          <term>FBM</term>
          <def>
            <p>Ffilamin binding motif</p>
          </def>
        </def-item>
        <def-item>
          <term>D3R</term>
          <def>
            <p>D3 dopamine receptor</p>
          </def>
        </def-item>
        <def-item>
          <term>ITC</term>
          <def>
            <p>isothermal titration calorimetry</p>
          </def>
        </def-item>
        <def-item>
          <term>NMR</term>
          <def>
            <p>nuclear magnetic resonance.</p>
          </def>
        </def-item>
      </def-list>
    </glossary>
    <ref-list>
      <title>References</title>
      <ref id="ref1">
        <mixed-citation publication-type="journal" id="cit1"><name><surname>Magalhaes</surname><given-names>A. C.</given-names></name>; <name><surname>Dunn</surname><given-names>H.</given-names></name>; <name><surname>Ferguson</surname><given-names>S. S.</given-names></name> (<year>2012</year>) <article-title>Regulation of GPCR activity, trafficking
and localization by GPCR-interacting proteins</article-title>. <source>Br. J. Pharmacol.</source>
<volume>165</volume>, <fpage>1717</fpage>â<lpage>1736</lpage><pub-id pub-id-type="doi">10.1111/j.1476-5381.2011.01552.x</pub-id>.<pub-id pub-id-type="pmid">21699508</pub-id></mixed-citation>
      </ref>
      <ref id="ref2">
        <mixed-citation publication-type="journal" id="cit2"><name><surname>Ma</surname><given-names>X.</given-names></name>; <name><surname>Zhao</surname><given-names>Y.</given-names></name>; <name><surname>Daaka</surname><given-names>Y.</given-names></name>; <name><surname>Nie</surname><given-names>Z.</given-names></name> (<year>2012</year>) <article-title>Acute activation of
Î²2-adrenergic receptor regulates focal adhesions through Î²Arrestin2-
and p115RhoGEF protein-mediated activation of RhoA</article-title>. <source>J. Biol. Chem.</source>
<volume>287</volume>, <fpage>18925</fpage>â<lpage>18936</lpage><pub-id pub-id-type="doi">10.1074/jbc.M112.352260</pub-id>.<pub-id pub-id-type="pmid">22500016</pub-id></mixed-citation>
      </ref>
      <ref id="ref3">
        <mixed-citation publication-type="journal" id="cit3"><name><surname>Cotton</surname><given-names>M.</given-names></name>; <name><surname>Claing</surname><given-names>A.</given-names></name> (<year>2009</year>) <article-title>G protein-coupled receptors stimulation and the control
of cell migration</article-title>. <source>Cell. Signalling</source>
<volume>21</volume>, <fpage>1045</fpage>â<lpage>1053</lpage><pub-id pub-id-type="doi">10.1016/j.cellsig.2009.02.008</pub-id>.<pub-id pub-id-type="pmid">19249352</pub-id></mixed-citation>
      </ref>
      <ref id="ref4">
        <mixed-citation publication-type="journal" id="cit4"><name><surname>Bockaert</surname><given-names>J.</given-names></name>; <name><surname>Pin</surname><given-names>J. P.</given-names></name> (<year>1999</year>) <article-title>Molecular tinkering
of G protein-coupled receptors:
an evolutionary success</article-title>. <source>EMBO J.</source>
<volume>18</volume>, <fpage>1723</fpage>â<lpage>1729</lpage><pub-id pub-id-type="doi">10.1093/emboj/18.7.1723</pub-id>.<pub-id pub-id-type="pmid">10202136</pub-id></mixed-citation>
      </ref>
      <ref id="ref5">
        <mixed-citation publication-type="journal" id="cit5"><name><surname>Vinson</surname><given-names>G. P.</given-names></name>; <name><surname>Barker</surname><given-names>S.</given-names></name>; <name><surname>Puddefoot</surname><given-names>J. R.</given-names></name> (<year>2012</year>) <article-title>The renin-angiotensin
system in the
breast and breast cancer</article-title>. <source>Endocr.-Relat. Cancer</source>
<volume>19</volume>, <fpage>R1</fpage>â<lpage>19</lpage><pub-id pub-id-type="doi">10.1530/ERC-11-0335</pub-id>.<pub-id pub-id-type="pmid">22180497</pub-id></mixed-citation>
      </ref>
      <ref id="ref6">
        <mixed-citation publication-type="journal" id="cit6"><name><surname>Ino</surname><given-names>K.</given-names></name>; <name><surname>Shibata</surname><given-names>K.</given-names></name>; <name><surname>Yamamoto</surname><given-names>E.</given-names></name>; <name><surname>Kajiyama</surname><given-names>H.</given-names></name>; <name><surname>Nawa</surname><given-names>A.</given-names></name>; <name><surname>Mabuchi</surname><given-names>Y.</given-names></name>; <name><surname>Yagi</surname><given-names>S.</given-names></name>; <name><surname>Minami</surname><given-names>S.</given-names></name>; <name><surname>Tanizaki</surname><given-names>Y.</given-names></name>; <name><surname>Kobayashi</surname><given-names>A.</given-names></name>; <name><surname>Kikkawa</surname><given-names>F.</given-names></name> (<year>2011</year>) <article-title>Role of the renin-angiotensin system
in gynecologic cancers</article-title>. <source>Curr. Cancer Drug Targets</source>
<volume>11</volume>, <fpage>405</fpage>â<lpage>411</lpage><pub-id pub-id-type="doi">10.2174/156800911795538057</pub-id>.<pub-id pub-id-type="pmid">21395551</pub-id></mixed-citation>
      </ref>
      <ref id="ref7">
        <mixed-citation publication-type="journal" id="cit7"><name><surname>Arrieta</surname><given-names>O.</given-names></name>; <name><surname>Pineda-Olvera</surname><given-names>B.</given-names></name>; <name><surname>Guevara-Salazar</surname><given-names>P.</given-names></name>; <name><surname>HernÃ¡ndez-Pedro</surname><given-names>N.</given-names></name>; <name><surname>Morales-Espinosa</surname><given-names>D.</given-names></name>; <name><surname>CerÃ³n-Lizarraga</surname><given-names>T. L.</given-names></name>; <name><surname>GonzÃ¡lez-De
la Rosa</surname><given-names>C. H.</given-names></name>; <name><surname>Rembao</surname><given-names>D.</given-names></name>; <name><surname>Segura-Pacheco</surname><given-names>B.</given-names></name>; <name><surname>Sotelo</surname><given-names>J.</given-names></name> (<year>2008</year>) <article-title>Expression of AT1 and AT2 angiotensin receptors in
astrocytomas is associated with poor prognosis</article-title>. <source>Br. J. Cancer</source>
<volume>99</volume>, <fpage>160</fpage>â<lpage>166</lpage><pub-id pub-id-type="doi">10.1038/sj.bjc.6604431</pub-id>.<pub-id pub-id-type="pmid">18594540</pub-id></mixed-citation>
      </ref>
      <ref id="ref8">
        <mixed-citation publication-type="journal" id="cit8"><name><surname>Chow</surname><given-names>L.</given-names></name>; <name><surname>Rezmann</surname><given-names>L.</given-names></name>; <name><surname>Catt</surname><given-names>K. J.</given-names></name>; <name><surname>Louis</surname><given-names>W. J.</given-names></name>; <name><surname>Frauman</surname><given-names>A. G.</given-names></name>; <name><surname>Nahmias</surname><given-names>C.</given-names></name>; <name><surname>Louis</surname><given-names>S. N.</given-names></name> (<year>2009</year>) <article-title>Role of the renin-angiotensin system
in prostate cancer</article-title>. <source>Mol. Cell. Endocrinol.</source>
<volume>302</volume>, <fpage>219</fpage>â<lpage>229</lpage><pub-id pub-id-type="doi">10.1016/j.mce.2008.08.032</pub-id>.<pub-id pub-id-type="pmid">18824067</pub-id></mixed-citation>
      </ref>
      <ref id="ref9">
        <mixed-citation publication-type="journal" id="cit9"><name><surname>OâHayre</surname><given-names>M.</given-names></name>; <name><surname>Degese</surname><given-names>M. S.</given-names></name>; <name><surname>Gutkind</surname><given-names>J. S.</given-names></name> (<year>2014</year>) <article-title>Novel insights
into G protein and
G protein-coupled receptor signaling in cancer</article-title>. <source>Curr. Opin. Cell Biol.</source>
<volume>27</volume>, <fpage>126</fpage>â<lpage>135</lpage><pub-id pub-id-type="doi">10.1016/j.ceb.2014.01.005</pub-id>.<pub-id pub-id-type="pmid">24508914</pub-id></mixed-citation>
      </ref>
      <ref id="ref10">
        <mixed-citation publication-type="journal" id="cit10"><name><surname>Pilar-Cuellar</surname><given-names>F.</given-names></name>; <name><surname>Vidal</surname><given-names>R.</given-names></name>; <name><surname>DÃ­az</surname><given-names>A.</given-names></name>; <name><surname>Castro</surname><given-names>E.</given-names></name>; <name><surname>dos Anjos</surname><given-names>S.</given-names></name>; <name><surname>Pascual-Brazo</surname><given-names>J.</given-names></name>; <name><surname>Linge</surname><given-names>R.</given-names></name>; <name><surname>Vargas</surname><given-names>V.</given-names></name>; <name><surname>Blanco</surname><given-names>H.</given-names></name>; <name><surname>MartÃ­nez-Villayandre</surname><given-names>B.</given-names></name>; <name><surname>Pazos</surname><given-names>Ã.</given-names></name>; <name><surname>ValdizÃ¡n</surname><given-names>E. M.</given-names></name> (<year>2013</year>) <article-title>Neural
plasticity and proliferation in the generation of antidepressant effects:
hippocampal implication</article-title>. <source>Neural Plast.</source>
<volume>2013</volume>(<issue>1</issue>), <fpage>21</fpage><pub-id pub-id-type="doi">10.1155/2013/537265</pub-id>.</mixed-citation>
      </ref>
      <ref id="ref11">
        <mixed-citation publication-type="journal" id="cit11"><name><surname>van
der Flier</surname><given-names>A.</given-names></name>; <name><surname>Sonnenberg</surname><given-names>A.</given-names></name> (<year>2001</year>) <article-title>Structural and functional aspects
of filamins</article-title>. <source>Biochim. Biophys. Acta, Mol. Cell
Res.</source>
<volume>1538</volume>, <fpage>99</fpage>â<lpage>117</lpage><pub-id pub-id-type="doi">10.1016/S0167-4889(01)00072-6</pub-id>.</mixed-citation>
      </ref>
      <ref id="ref12">
        <mixed-citation publication-type="journal" id="cit12"><name><surname>Nakamura</surname><given-names>F.</given-names></name>; <name><surname>Stossel</surname><given-names>T. P.</given-names></name>; <name><surname>Hartwig</surname><given-names>J. H.</given-names></name> (<year>2011</year>) <article-title>The filamins: organizers of cell
structure and function</article-title>. <source>Cell Adh. Migr</source>
<volume>5</volume>, <fpage>160</fpage>â<lpage>169</lpage><pub-id pub-id-type="doi">10.4161/cam.5.2.14401</pub-id>.<pub-id pub-id-type="pmid">21169733</pub-id></mixed-citation>
      </ref>
      <ref id="ref13">
        <mixed-citation publication-type="journal" id="cit13"><name><surname>Lin</surname><given-names>R.</given-names></name>; <name><surname>Karpa</surname><given-names>K.</given-names></name>; <name><surname>Kabbani</surname><given-names>N.</given-names></name>; <name><surname>Goldman-Rakic</surname><given-names>P.</given-names></name>; <name><surname>Levenson</surname><given-names>R.</given-names></name> (<year>2001</year>) <article-title>Dopamine D2 and D3 receptors are
linked to the actin
cytoskeleton via interaction with filamin A</article-title>. <source>Proc. Natl. Acad. Sci. U. S. A.</source>
<volume>98</volume>, <fpage>5258</fpage>â<lpage>5263</lpage><pub-id pub-id-type="doi">10.1073/pnas.011538198</pub-id>.<pub-id pub-id-type="pmid">11320256</pub-id></mixed-citation>
      </ref>
      <ref id="ref14">
        <mixed-citation publication-type="journal" id="cit14"><name><surname>Li</surname><given-names>M.</given-names></name>; <name><surname>Bermak</surname><given-names>J. C.</given-names></name>; <name><surname>Wang</surname><given-names>Z. W.</given-names></name>; <name><surname>Zhou</surname><given-names>Q. Y.</given-names></name> (<year>2000</year>) <article-title>Modulation of dopamine
D(2) receptor signaling by actin-binding protein (ABP-280)</article-title>. <source>Mol. Pharmacol.</source>
<volume>57</volume>, <fpage>446</fpage>â<lpage>452</lpage>.<pub-id pub-id-type="pmid">10692483</pub-id></mixed-citation>
      </ref>
      <ref id="ref15">
        <mixed-citation publication-type="journal" id="cit15"><name><surname>Li</surname><given-names>M.</given-names></name>; <name><surname>Li</surname><given-names>C.</given-names></name>; <name><surname>Weingarten</surname><given-names>P.</given-names></name>; <name><surname>Bunzow</surname><given-names>J. R.</given-names></name>; <name><surname>Grandy</surname><given-names>D. K.</given-names></name>; <name><surname>Zhou</surname><given-names>Q. Y.</given-names></name> (<year>2002</year>) <article-title>Association
of dopamine D(3) receptors with actin-binding protein 280 (ABP-280)</article-title>. <source>Biochem. Pharmacol.</source>
<volume>63</volume>, <fpage>859</fpage>â<lpage>863</lpage><pub-id pub-id-type="doi">10.1016/S0006-2952(01)00932-7</pub-id>.<pub-id pub-id-type="pmid">11911837</pub-id></mixed-citation>
      </ref>
      <ref id="ref16">
        <mixed-citation publication-type="journal" id="cit16"><name><surname>Seck</surname><given-names>T.</given-names></name>; <name><surname>Baron</surname><given-names>R.</given-names></name>; <name><surname>Horne</surname><given-names>W. C.</given-names></name> (<year>2003</year>) <article-title>Binding of filamin
to the C-terminal
tail of the calcitonin receptor controls recycling</article-title>. <source>J. Biol. Chem.</source>
<volume>278</volume>, <fpage>10408</fpage>â<lpage>10416</lpage><pub-id pub-id-type="doi">10.1074/jbc.M209655200</pub-id>.<pub-id pub-id-type="pmid">12531889</pub-id></mixed-citation>
      </ref>
      <ref id="ref17">
        <mixed-citation publication-type="journal" id="cit17"><name><surname>Minsaas</surname><given-names>L.</given-names></name>; <name><surname>PlanagumÃ </surname><given-names>J.</given-names></name>; <name><surname>Madziva</surname><given-names>M.</given-names></name>; <name><surname>Krakstad</surname><given-names>B. F.</given-names></name>; <name><surname>MasiÃ -BalaguÃ©</surname><given-names>M.</given-names></name>; <name><surname>Katz</surname><given-names>A. A.</given-names></name>; <name><surname>Aragay</surname><given-names>A. M.</given-names></name> (<year>2010</year>) <article-title>Filamin a binds to CCR2B and regulates
its internalization</article-title>. <source>PLoS One</source>
<volume>5</volume>, <fpage>e12212</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0012212</pub-id>.<pub-id pub-id-type="pmid">20808917</pub-id></mixed-citation>
      </ref>
      <ref id="ref18">
        <mixed-citation publication-type="journal" id="cit18"><name><surname>Onoprishvili</surname><given-names>I.</given-names></name>; <name><surname>Andria</surname><given-names>M. L.</given-names></name>; <name><surname>Kramer</surname><given-names>H. K.</given-names></name>; <name><surname>Ancevska-Taneva</surname><given-names>N.</given-names></name>; <name><surname>Hiller</surname><given-names>J. M.</given-names></name>; <name><surname>Simon</surname><given-names>E. J.</given-names></name> (<year>2003</year>) <article-title>Interaction between
the mu opioid
receptor and filamin A is involved in receptor regulation and trafficking</article-title>. <source>Mol. Pharmacol.</source>
<volume>64</volume>, <fpage>1092</fpage>â<lpage>1100</lpage><pub-id pub-id-type="doi">10.1124/mol.64.5.1092</pub-id>.<pub-id pub-id-type="pmid">14573758</pub-id></mixed-citation>
      </ref>
      <ref id="ref19">
        <mixed-citation publication-type="journal" id="cit19"><name><surname>Onoprishvili</surname><given-names>I.</given-names></name>; <name><surname>Simon</surname><given-names>E. J.</given-names></name> (<year>2007</year>) <article-title>Chronic morphine treatment up-regulates mu opioid receptor
binding in cells lacking filamin A</article-title>. <source>Brain Res.</source>
<volume>1177</volume>, <fpage>9</fpage>â<lpage>18</lpage><pub-id pub-id-type="doi">10.1016/j.brainres.2007.08.020</pub-id>.<pub-id pub-id-type="pmid">17897634</pub-id></mixed-citation>
      </ref>
      <ref id="ref20">
        <mixed-citation publication-type="journal" id="cit20"><name><surname>Simon</surname><given-names>E. J.</given-names></name>; <name><surname>Onoprishvili</surname><given-names>I.</given-names></name> (<year>2010</year>) <article-title>The interaction
between the mu opioid receptor and
filamin A</article-title>. <source>Neurochem. Res.</source>
<volume>35</volume>, <fpage>1859</fpage>â<lpage>1866</lpage><pub-id pub-id-type="doi">10.1007/s11064-010-0261-9</pub-id>.<pub-id pub-id-type="pmid">20857334</pub-id></mixed-citation>
      </ref>
      <ref id="ref21">
        <mixed-citation publication-type="journal" id="cit21"><name><surname>Awata</surname><given-names>H.</given-names></name>; <name><surname>Huang</surname><given-names>C.</given-names></name>; <name><surname>Handlogten</surname><given-names>M. E.</given-names></name>; <name><surname>Miller</surname><given-names>R. T.</given-names></name> (<year>2001</year>) <article-title>Interaction of the
calcium-sensing receptor and filamin, a potential scaffolding protein</article-title>. <source>J. Biol. Chem.</source>
<volume>276</volume>, <fpage>34871</fpage>â<lpage>34879</lpage><pub-id pub-id-type="doi">10.1074/jbc.M100775200</pub-id>.<pub-id pub-id-type="pmid">11390379</pub-id></mixed-citation>
      </ref>
      <ref id="ref22">
        <mixed-citation publication-type="journal" id="cit22"><name><surname>Hjalm</surname><given-names>G.</given-names></name>; <name><surname>MacLeod</surname><given-names>R. J.</given-names></name>; <name><surname>Kifor</surname><given-names>O.</given-names></name>; <name><surname>Chattopadhyay</surname><given-names>N.</given-names></name>; <name><surname>Brown</surname><given-names>E. M.</given-names></name> (<year>2001</year>) <article-title>Filamin-A binds to the carboxyl-terminal tail of the
calcium-sensing receptor, an interaction that participates in CaR-mediated
activation of mitogen-activated protein kinase</article-title>. <source>J. Biol. Chem.</source>
<volume>276</volume>, <fpage>34880</fpage>â<lpage>34887</lpage><pub-id pub-id-type="doi">10.1074/jbc.M100784200</pub-id>.<pub-id pub-id-type="pmid">11390380</pub-id></mixed-citation>
      </ref>
      <ref id="ref23">
        <mixed-citation publication-type="journal" id="cit23"><name><surname>Pi</surname><given-names>M.</given-names></name>; <name><surname>Spurney</surname><given-names>R. F.</given-names></name>; <name><surname>Tu</surname><given-names>Q.</given-names></name>; <name><surname>Hinson</surname><given-names>T.</given-names></name>; <name><surname>Quarles</surname><given-names>L. D.</given-names></name> (<year>2002</year>) <article-title>Calcium-sensing
receptor activation of rho involves filamin and rho-guanine nucleotide
exchange factor</article-title>. <source>Endocrinology</source>
<volume>143</volume>, <fpage>3830</fpage>â<lpage>3838</lpage><pub-id pub-id-type="doi">10.1210/en.2002-220240</pub-id>.<pub-id pub-id-type="pmid">12239094</pub-id></mixed-citation>
      </ref>
      <ref id="ref24">
        <mixed-citation publication-type="journal" id="cit24"><name><surname>Zhang</surname><given-names>M.</given-names></name>; <name><surname>Breitwieser</surname><given-names>G. E.</given-names></name> (<year>2005</year>) <article-title>High affinity
interaction with filamin A protects against
calcium-sensing receptor degradation</article-title>. <source>J. Biol.
Chem.</source>
<volume>280</volume>, <fpage>11140</fpage>â<lpage>11146</lpage><pub-id pub-id-type="doi">10.1074/jbc.M412242200</pub-id>.<pub-id pub-id-type="pmid">15657061</pub-id></mixed-citation>
      </ref>
      <ref id="ref25">
        <mixed-citation publication-type="journal" id="cit25"><name><surname>Rey</surname><given-names>O.</given-names></name>; <name><surname>Young</surname><given-names>S. H.</given-names></name>; <name><surname>Jacamo</surname><given-names>R.</given-names></name>; <name><surname>Moyer</surname><given-names>M. P.</given-names></name>; <name><surname>Rozengurt</surname><given-names>E.</given-names></name> (<year>2010</year>) <article-title>Extracellular
calcium sensing receptor stimulation in human colonic epithelial cells
induces intracellular calcium oscillations and proliferation inhibition</article-title>. <source>J. Cell. Physiol.</source>
<volume>225</volume>, <fpage>73</fpage>â<lpage>83</lpage><pub-id pub-id-type="doi">10.1002/jcp.22198</pub-id>.<pub-id pub-id-type="pmid">20648625</pub-id></mixed-citation>
      </ref>
      <ref id="ref26">
        <mixed-citation publication-type="journal" id="cit26"><name><surname>Chakravarti</surname><given-names>B.</given-names></name>; <name><surname>Chattopadhyay</surname><given-names>N.</given-names></name>; <name><surname>Brown</surname><given-names>E. M.</given-names></name> (<year>2012</year>) <article-title>Signaling through the extracellular
calcium-sensing receptor (CaSR)</article-title>. <source>Adv. Exp. Med.
Biol.</source>
<volume>740</volume>, <fpage>103</fpage>â<lpage>142</lpage><pub-id pub-id-type="doi">10.1007/978-94-007-2888-2_5</pub-id>.<pub-id pub-id-type="pmid">22453940</pub-id></mixed-citation>
      </ref>
      <ref id="ref27">
        <mixed-citation publication-type="journal" id="cit27"><name><surname>Enz</surname><given-names>R.</given-names></name> (<year>2002</year>) <article-title>The actin-binding
protein Filamin-A interacts with the metabotropic glutamate receptor
type 7</article-title>. <source>FEBS Lett.</source>
<volume>514</volume>, <fpage>184</fpage>â<lpage>188</lpage><pub-id pub-id-type="doi">10.1016/S0014-5793(02)02361-X</pub-id>.<pub-id pub-id-type="pmid">11943148</pub-id></mixed-citation>
      </ref>
      <ref id="ref28">
        <mixed-citation publication-type="journal" id="cit28"><name><surname>Enz</surname><given-names>R.</given-names></name>; <name><surname>Croci</surname><given-names>C.</given-names></name> (<year>2003</year>) <article-title>Different binding motifs
in metabotropic glutamate receptor type
7b for filamin A, protein phosphatase 1C, protein interacting with
protein kinase C (PICK) 1 and syntenin allow the formation of multimeric
protein complexes</article-title>. <source>Biochem. J.</source>
<volume>372</volume>, <fpage>183</fpage>â<lpage>191</lpage><pub-id pub-id-type="doi">10.1042/bj20021750</pub-id>.<pub-id pub-id-type="pmid">12570872</pub-id></mixed-citation>
      </ref>
      <ref id="ref29">
        <mixed-citation publication-type="journal" id="cit29"><name><surname>Najib</surname><given-names>S.</given-names></name>; <name><surname>Saint-Laurent</surname><given-names>N.</given-names></name>; <name><surname>EstÃ¨ve</surname><given-names>J. P.</given-names></name>; <name><surname>Schulz</surname><given-names>S.</given-names></name>; <name><surname>Boutet-Robinet</surname><given-names>E.</given-names></name>; <name><surname>Fourmy</surname><given-names>D.</given-names></name>; <name><surname>LÃ¤ttig</surname><given-names>J.</given-names></name>; <name><surname>Mollereau</surname><given-names>C.</given-names></name>; <name><surname>Pyronnet</surname><given-names>S.</given-names></name>; <name><surname>Susini</surname><given-names>C.</given-names></name>; <name><surname>Bousquet</surname><given-names>C.</given-names></name> (<year>2012</year>) <article-title>A switch of G protein-coupled
receptor binding preference from phosphoinositide 3-kinase (PI3K)-p85
to filamin A negatively controls the PI3K pathway</article-title>. <source>Mol. Cell. Biol.</source>
<volume>32</volume>, <fpage>1004</fpage>â<lpage>1016</lpage><pub-id pub-id-type="doi">10.1128/MCB.06252-11</pub-id>.<pub-id pub-id-type="pmid">22203038</pub-id></mixed-citation>
      </ref>
      <ref id="ref30">
        <mixed-citation publication-type="journal" id="cit30"><name><surname>Peverelli</surname><given-names>E.</given-names></name>; <name><surname>Giardino</surname><given-names>E.</given-names></name>; <name><surname>Vitali</surname><given-names>E.</given-names></name>; <name><surname>Treppiedi</surname><given-names>D.</given-names></name>; <name><surname>Lania</surname><given-names>A. G.</given-names></name>; <name><surname>Mantovani</surname><given-names>G.</given-names></name> (<year>2014</year>) <article-title>Filamin A in Somatostatin and Dopamine
Receptor Regulation in Pituitary and the Role of cAMP/PKA Dependent
Phosphorylation</article-title>. <source>Horm. Metab. Res.</source>
<volume>46</volume>, <fpage>845</fpage>â<lpage>853</lpage><pub-id pub-id-type="doi">10.1055/s-0034-1384520</pub-id>.<pub-id pub-id-type="pmid">25068602</pub-id></mixed-citation>
      </ref>
      <ref id="ref31">
        <mixed-citation publication-type="journal" id="cit31"><name><surname>Kajita</surname><given-names>M.</given-names></name>; <name><surname>Sugimura</surname><given-names>K.</given-names></name>; <name><surname>Ohoka</surname><given-names>A.</given-names></name>; <name><surname>Burden</surname><given-names>J.</given-names></name>; <name><surname>Suganuma</surname><given-names>H.</given-names></name>; <name><surname>Ikegawa</surname><given-names>M.</given-names></name>; <name><surname>Shimada</surname><given-names>T.</given-names></name>; <name><surname>Kitamura</surname><given-names>T.</given-names></name>; <name><surname>Shindoh</surname><given-names>M.</given-names></name>; <name><surname>Ishikawa</surname><given-names>S.</given-names></name>; <name><surname>Yamamoto</surname><given-names>S.</given-names></name>; <name><surname>Saitoh</surname><given-names>S.</given-names></name>; <name><surname>Yako</surname><given-names>Y.</given-names></name>; <name><surname>Takahashi</surname><given-names>R.</given-names></name>; <name><surname>Okajima</surname><given-names>T.</given-names></name>; <name><surname>Kikuta</surname><given-names>J.</given-names></name>; <name><surname>Maijima</surname><given-names>Y.</given-names></name>; <name><surname>Ishii</surname><given-names>M.</given-names></name>; <name><surname>Tada</surname><given-names>M.</given-names></name>; <name><surname>Fujita</surname><given-names>Y.</given-names></name> (<year>2014</year>) <article-title>Filamin acts as a key
regulator in epithelial defence against transformed cells</article-title>. <source>Nat. Commun.</source>
<volume>5</volume>, <fpage>4428</fpage><pub-id pub-id-type="doi">10.1038/ncomms5428</pub-id>.<pub-id pub-id-type="pmid">25079702</pub-id></mixed-citation>
      </ref>
      <ref id="ref32">
        <mixed-citation publication-type="journal" id="cit32"><name><surname>Ithychanda</surname><given-names>S. S.</given-names></name>; <name><surname>Hsu</surname><given-names>D.</given-names></name>; <name><surname>Li</surname><given-names>H.</given-names></name>; <name><surname>Yan</surname><given-names>L.</given-names></name>; <name><surname>Liu</surname><given-names>D. D.</given-names></name>; <name><surname>Das</surname><given-names>M.</given-names></name>; <name><surname>Plow</surname><given-names>E. F.</given-names></name>; <name><surname>Qin</surname><given-names>J.</given-names></name> (<year>2009</year>) <article-title>Identification
and characterization
of multiple similar ligand-binding repeats in filamin: implication
on filamin-mediated receptor clustering and cross-talk</article-title>. <source>J. Biol. Chem.</source>
<volume>284</volume>, <fpage>35113</fpage>â<lpage>35121</lpage><pub-id pub-id-type="doi">10.1074/jbc.M109.060954</pub-id>.<pub-id pub-id-type="pmid">19828450</pub-id></mixed-citation>
      </ref>
      <ref id="ref33">
        <mixed-citation publication-type="journal" id="cit33"><name><surname>Liu</surname><given-names>J.</given-names></name>; <name><surname>Das</surname><given-names>M.</given-names></name>; <name><surname>Yang</surname><given-names>J.</given-names></name>; <name><surname>Ithychanda</surname><given-names>S. S.</given-names></name>; <name><surname>Yakubenko</surname><given-names>V. P.</given-names></name>; <name><surname>Plow</surname><given-names>E. F.</given-names></name>; <name><surname>Qin</surname><given-names>J.</given-names></name> (<year>2015</year>) <article-title>Structural mechanism of integrin
inactivation by filamin</article-title>. <source>Nat. Struct. Mol. Biol.</source>
<volume>22</volume>, <fpage>383</fpage>â<lpage>389</lpage><pub-id pub-id-type="doi">10.1038/nsmb.2999</pub-id>.<pub-id pub-id-type="pmid">25849143</pub-id></mixed-citation>
      </ref>
      <ref id="ref34">
        <mixed-citation publication-type="journal" id="cit34"><name><surname>Lad</surname><given-names>Y.</given-names></name>; <name><surname>Kiema</surname><given-names>T.</given-names></name>; <name><surname>Jiang</surname><given-names>P.</given-names></name>; <name><surname>PentikÃ¤inen</surname><given-names>O. T.</given-names></name>; <name><surname>Coles</surname><given-names>C. H.</given-names></name>; <name><surname>Campbell</surname><given-names>I. D.</given-names></name>; <name><surname>Calderwood</surname><given-names>D. A.</given-names></name>; <name><surname>YlÃ¤nne</surname><given-names>J.</given-names></name> (<year>2007</year>) <article-title>Structure of three tandem filamin
domains reveals auto-inhibition
of ligand binding</article-title>. <source>EMBO J.</source>
<volume>26</volume>, <fpage>3993</fpage>â<lpage>4004</lpage><pub-id pub-id-type="doi">10.1038/sj.emboj.7601827</pub-id>.<pub-id pub-id-type="pmid">17690686</pub-id></mixed-citation>
      </ref>
      <ref id="ref35">
        <mixed-citation publication-type="journal" id="cit35"><name><surname>Ithychanda</surname><given-names>S. S.</given-names></name>; <name><surname>Qin</surname><given-names>J.</given-names></name> (<year>2011</year>) <article-title>Evidence for multisite
ligand binding and stretching of filamin by
integrin and migfilin</article-title>. <source>Biochemistry</source>
<volume>50</volume>, <fpage>4229</fpage>â<lpage>4231</lpage><pub-id pub-id-type="doi">10.1021/bi2003229</pub-id>.<pub-id pub-id-type="pmid">21524097</pub-id></mixed-citation>
      </ref>
      <ref id="ref36">
        <mixed-citation publication-type="journal" id="cit36"><name><surname>Jay</surname><given-names>D.</given-names></name>; <name><surname>Garcia</surname><given-names>E. J.</given-names></name>; <name><surname>Lara</surname><given-names>J. E.</given-names></name>; <name><surname>Medina</surname><given-names>M. A.</given-names></name>; <name><surname>de la
Luz Ibarra</surname><given-names>M.</given-names></name> (<year>2000</year>) <article-title>Determination of a cAMP-dependent protein kinase phosphorylation
site in the C-terminal region of human endothelial actin-binding protein</article-title>. <source>Arch. Biochem. Biophys.</source>
<volume>377</volume>, <fpage>80</fpage>â<lpage>84</lpage><pub-id pub-id-type="doi">10.1006/abbi.2000.1762</pub-id>.<pub-id pub-id-type="pmid">10775444</pub-id></mixed-citation>
      </ref>
      <ref id="ref37">
        <mixed-citation publication-type="journal" id="cit37"><name><surname>Ithychanda</surname><given-names>S. S.</given-names></name>; <name><surname>Fang</surname><given-names>X.</given-names></name>; <name><surname>Mohan</surname><given-names>M. L.</given-names></name>; <name><surname>Zhu</surname><given-names>L.</given-names></name>; <name><surname>Tirupula</surname><given-names>K. C.</given-names></name>; <name><surname>Naga Prasad</surname><given-names>S. V.</given-names></name>; <name><surname>Wang</surname><given-names>Y. X.</given-names></name>; <name><surname>Karnik</surname><given-names>S.</given-names></name>; <name><surname>Qin</surname><given-names>J.</given-names></name> (<year>2015</year>) <article-title>A mechanism
of global shape-dependent recognition and phosphorylation of filamin
by protein kinase A</article-title>. <source>J. Biol. Chem.</source>
<volume>290</volume>, <fpage>8527</fpage>â<lpage>8538</lpage><pub-id pub-id-type="doi">10.1074/jbc.M114.633446</pub-id>.<pub-id pub-id-type="pmid">25666618</pub-id></mixed-citation>
      </ref>
      <ref id="ref38">
        <mixed-citation publication-type="journal" id="cit38"><name><surname>Nakamura</surname><given-names>F.</given-names></name>; <name><surname>Pudas</surname><given-names>R.</given-names></name>; <name><surname>Heikkinen</surname><given-names>O.</given-names></name>; <name><surname>Permi</surname><given-names>P.</given-names></name>; <name><surname>KilpelÃ¤inen</surname><given-names>I.</given-names></name>; <name><surname>Munday</surname><given-names>A. D.</given-names></name>; <name><surname>Hartwig</surname><given-names>J. H.</given-names></name>; <name><surname>Stossel</surname><given-names>T. P.</given-names></name>; <name><surname>YlÃ¤nne</surname><given-names>J.</given-names></name> (<year>2006</year>) <article-title>The structure
of the GPIb-filamin A complex</article-title>. <source>Blood</source>
<volume>107</volume>, <fpage>1925</fpage>â<lpage>1932</lpage><pub-id pub-id-type="doi">10.1182/blood-2005-10-3964</pub-id>.<pub-id pub-id-type="pmid">16293600</pub-id></mixed-citation>
      </ref>
      <ref id="ref39">
        <mixed-citation publication-type="journal" id="cit39"><name><surname>UniProt</surname><given-names>C.</given-names></name> (<year>2014</year>) <article-title>Activities
at the Universal Protein Resource (UniProt)</article-title>. <source>Nucleic Acids Res.</source>
<volume>42</volume>(<issue>Database Issue</issue>), <fpage>D191</fpage>â<lpage>D198</lpage><pub-id pub-id-type="doi">10.1093/nar/gkt1140</pub-id>.<pub-id pub-id-type="pmid">24253303</pub-id></mixed-citation>
      </ref>
      <ref id="ref40">
        <mixed-citation publication-type="journal" id="cit40"><name><surname>Baker</surname><given-names>N. A.</given-names></name>; <name><surname>Sept</surname><given-names>D.</given-names></name>; <name><surname>Joseph</surname><given-names>S.</given-names></name>; <name><surname>Holst</surname><given-names>M. J.</given-names></name>; <name><surname>McCammon</surname><given-names>J. A.</given-names></name> (<year>2001</year>) <article-title>Electrostatics
of nanosystems: application to microtubules and the ribosome</article-title>. <source>Proc. Natl. Acad. Sci. U. S. A.</source>
<volume>98</volume>, <fpage>10037</fpage>â<lpage>10041</lpage><pub-id pub-id-type="doi">10.1073/pnas.181342398</pub-id>.<pub-id pub-id-type="pmid">11517324</pub-id></mixed-citation>
      </ref>
      <ref id="ref41">
        <mixed-citation publication-type="journal" id="cit41"><name><surname>Delaglio</surname><given-names>F.</given-names></name>; <name><surname>Grzesiek</surname><given-names>S.</given-names></name>; <name><surname>Vuister</surname><given-names>G. W.</given-names></name>; <name><surname>Zhu</surname><given-names>G.</given-names></name>; <name><surname>Pfeifer</surname><given-names>J.</given-names></name>; <name><surname>Bax</surname><given-names>A.</given-names></name> (<year>1995</year>) <article-title>NMRPipe: a multidimensional spectral
processing system based on UNIX
pipes</article-title>. <source>J. Biomol. NMR</source>
<volume>6</volume>, <fpage>277</fpage>â<lpage>293</lpage><pub-id pub-id-type="doi">10.1007/BF00197809</pub-id>.<pub-id pub-id-type="pmid">8520220</pub-id></mixed-citation>
      </ref>
      <ref id="ref42">
        <mixed-citation publication-type="journal" id="cit42"><name><surname>Tirupula</surname><given-names>K. C.</given-names></name>; <name><surname>Desnoyer</surname><given-names>R.</given-names></name>; <name><surname>Speth</surname><given-names>R. C.</given-names></name>; <name><surname>Karnik</surname><given-names>S. S.</given-names></name> (<year>2014</year>) <article-title>Atypical signaling
and functional desensitization response of MAS receptor to Peptide
ligands</article-title>. <source>PLoS One</source>
<volume>9</volume>, <fpage>e103520</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0103520</pub-id>.<pub-id pub-id-type="pmid">25068582</pub-id></mixed-citation>
      </ref>
      <ref id="ref43">
        <mixed-citation publication-type="journal" id="cit43"><name><surname>Bhatnagar</surname><given-names>A.</given-names></name>; <name><surname>Unal</surname><given-names>H.</given-names></name>; <name><surname>Jagannathan</surname><given-names>R.</given-names></name>; <name><surname>Kaveti</surname><given-names>S.</given-names></name>; <name><surname>Duan</surname><given-names>Z. H.</given-names></name>; <name><surname>Yong</surname><given-names>S.</given-names></name>; <name><surname>Vasanji</surname><given-names>A.</given-names></name>; <name><surname>Kinter</surname><given-names>M.</given-names></name>; <name><surname>Desnoyer</surname><given-names>R.</given-names></name>; <name><surname>Karnik</surname><given-names>S. S.</given-names></name> (<year>2013</year>) <article-title>Interaction of G-protein
betagamma complex with chromatin
modulates GPCR-dependent gene regulation</article-title>. <source>PLoS
One</source>
<volume>8</volume>, <fpage>e52689</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0052689</pub-id>.<pub-id pub-id-type="pmid">23326349</pub-id></mixed-citation>
      </ref>
      <ref id="ref44">
        <mixed-citation publication-type="journal" id="cit44"><name><surname>Zhang</surname><given-names>H.</given-names></name>; <name><surname>Unal</surname><given-names>H.</given-names></name>; <name><surname>Gati</surname><given-names>C.</given-names></name>; <name><surname>Han</surname><given-names>G. W.</given-names></name>; <name><surname>Liu</surname><given-names>W.</given-names></name>; <name><surname>Zatsepin</surname><given-names>N. A.</given-names></name>; <name><surname>James</surname><given-names>D.</given-names></name>; <name><surname>Wang</surname><given-names>D.</given-names></name>; <name><surname>Nelson</surname><given-names>G.</given-names></name>; <name><surname>Weierstall</surname><given-names>U.</given-names></name>; <name><surname>Sawaya</surname><given-names>M. R.</given-names></name>; <name><surname>Xu</surname><given-names>Q.</given-names></name>; <name><surname>Messerschmidt</surname><given-names>M.</given-names></name>; <name><surname>Williams</surname><given-names>G. J.</given-names></name>; <name><surname>Boutet</surname><given-names>S.</given-names></name>; <name><surname>Yefanov</surname><given-names>O. M.</given-names></name>; <name><surname>White</surname><given-names>T. A.</given-names></name>; <name><surname>Wang</surname><given-names>C.</given-names></name>; <name><surname>Ishchenko</surname><given-names>A.</given-names></name>; <name><surname>Tirupula</surname><given-names>K. C.</given-names></name>; <name><surname>Desnoyer</surname><given-names>R.</given-names></name>; <name><surname>Coe</surname><given-names>J.</given-names></name>; <name><surname>Conrad</surname><given-names>C. E.</given-names></name>; <name><surname>Fromme</surname><given-names>P.</given-names></name>; <name><surname>Stevens</surname><given-names>R. C.</given-names></name>; <name><surname>Katritch</surname><given-names>V.</given-names></name>; <name><surname>Karnik</surname><given-names>S. S.</given-names></name>; <name><surname>Cherezov</surname><given-names>V.</given-names></name> (<year>2015</year>) <article-title>Structure of the Angiotensin receptor
revealed by serial femtosecond crystallography</article-title>. <source>Cell</source>
<volume>161</volume>, <fpage>833</fpage>â<lpage>844</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2015.04.011</pub-id>.<pub-id pub-id-type="pmid">25913193</pub-id></mixed-citation>
      </ref>
      <ref id="ref45">
        <mixed-citation publication-type="journal" id="cit45"><name><surname>McCune</surname><given-names>D. F.</given-names></name>; <name><surname>Edelmann</surname><given-names>S. E.</given-names></name>; <name><surname>Olges</surname><given-names>J. R.</given-names></name>; <name><surname>Post</surname><given-names>G. R.</given-names></name>; <name><surname>Waldrop</surname><given-names>B. A.</given-names></name>; <name><surname>Waugh</surname><given-names>D. J.</given-names></name>; <name><surname>Perez</surname><given-names>D. M.</given-names></name>; <name><surname>Piascik</surname><given-names>M. T.</given-names></name> (<year>2000</year>) <article-title>Regulation of the
cellular localization and signaling properties of the alpha(1B)- and
alpha(1D)-adrenoceptors by agonists and inverse agonists</article-title>. <source>Mol. Pharmacol.</source>
<volume>57</volume>, <fpage>659</fpage>â<lpage>666</lpage>.<pub-id pub-id-type="pmid">10727510</pub-id></mixed-citation>
      </ref>
      <ref id="ref46">
        <mixed-citation publication-type="journal" id="cit46"><name><surname>Perez</surname><given-names>D. M.</given-names></name>; <name><surname>Papay</surname><given-names>R. S.</given-names></name>; <name><surname>Shi</surname><given-names>T.</given-names></name> (<year>2009</year>) <article-title>alpha1-Adrenergic receptor stimulates
interleukin-6 expression and secretion through both mRNA stability
and transcriptional regulation: involvement of p38 mitogen-activated
protein kinase and nuclear factor-kappaB</article-title>. <source>Mol.
Pharmacol.</source>
<volume>76</volume>, <fpage>144</fpage>â<lpage>152</lpage><pub-id pub-id-type="doi">10.1124/mol.108.054320</pub-id>.<pub-id pub-id-type="pmid">19363165</pub-id></mixed-citation>
      </ref>
      <ref id="ref47">
        <mixed-citation publication-type="journal" id="cit47"><name><surname>Ithychanda</surname><given-names>S. S.</given-names></name>; <name><surname>Das</surname><given-names>M.</given-names></name>; <name><surname>Ma</surname><given-names>Y. Q.</given-names></name>; <name><surname>Ding</surname><given-names>K.</given-names></name>; <name><surname>Wang</surname><given-names>X.</given-names></name>; <name><surname>Gupta</surname><given-names>S.</given-names></name>; <name><surname>Wu</surname><given-names>C.</given-names></name>; <name><surname>Plow</surname><given-names>E. F.</given-names></name>; <name><surname>Qin</surname><given-names>J.</given-names></name> (<year>2009</year>) <article-title>Migfilin, a molecular switch in regulation
of integrin activation</article-title>. <source>J. Biol. Chem.</source>
<volume>284</volume>, <fpage>4713</fpage>â<lpage>4722</lpage><pub-id pub-id-type="doi">10.1074/jbc.M807719200</pub-id>.<pub-id pub-id-type="pmid">19074766</pub-id></mixed-citation>
      </ref>
      <ref id="ref48">
        <mixed-citation publication-type="journal" id="cit48"><name><surname>Capettini</surname><given-names>L. S.</given-names></name>; <name><surname>Montecucco</surname><given-names>F.</given-names></name>; <name><surname>Mach</surname><given-names>F.</given-names></name>; <name><surname>Stergiopulos</surname><given-names>N.</given-names></name>; <name><surname>Santos</surname><given-names>R. A.</given-names></name>; <name><surname>da Silva</surname><given-names>R. F.</given-names></name> (<year>2012</year>) <article-title>Role of
renin-angiotensin system
in inflammation, immunity and aging</article-title>. <source>Curr. Pharm.
Des.</source>
<volume>18</volume>, <fpage>963</fpage>â<lpage>970</lpage><pub-id pub-id-type="doi">10.2174/138161212799436593</pub-id>.<pub-id pub-id-type="pmid">22283774</pub-id></mixed-citation>
      </ref>
      <ref id="ref49">
        <mixed-citation publication-type="journal" id="cit49"><name><surname>Zhang</surname><given-names>T.</given-names></name>; <name><surname>Li</surname><given-names>Z.</given-names></name>; <name><surname>Dang</surname><given-names>H.</given-names></name>; <name><surname>Chen</surname><given-names>R.</given-names></name>; <name><surname>Liaw</surname><given-names>C.</given-names></name>; <name><surname>Tran</surname><given-names>T. A.</given-names></name>; <name><surname>Boatman</surname><given-names>P. D.</given-names></name>; <name><surname>Connolly</surname><given-names>D. T.</given-names></name>; <name><surname>Adams</surname><given-names>J. W.</given-names></name> (<year>2012</year>) <article-title>Inhibition of Mas
G-protein signaling improves coronary blood flow, reduces myocardial
infarct size, and provides long-term cardioprotection</article-title>. <source>Am. J. Physiol. Heart Circ. Physiol.</source>
<volume>302</volume>, <fpage>H299</fpage>â<lpage>311</lpage><pub-id pub-id-type="doi">10.1152/ajpheart.00723.2011</pub-id>.<pub-id pub-id-type="pmid">22003054</pub-id></mixed-citation>
      </ref>
      <ref id="ref50">
        <mixed-citation publication-type="journal" id="cit50"><name><surname>Ohta</surname><given-names>Y.</given-names></name>; <name><surname>Hartwig</surname><given-names>J. H.</given-names></name> (<year>1996</year>) <article-title>Phosphorylation
of actin-binding protein 280 by growth
factors is mediated by p90 ribosomal protein S6 kinase</article-title>. <source>J. Biol. Chem.</source>
<volume>271</volume>, <fpage>11858</fpage>â<lpage>11864</lpage><pub-id pub-id-type="doi">10.1074/jbc.271.20.11858</pub-id>.<pub-id pub-id-type="pmid">8662682</pub-id></mixed-citation>
      </ref>
      <ref id="ref51">
        <mixed-citation publication-type="journal" id="cit51"><name><surname>Wang</surname><given-names>Q.</given-names></name>; <name><surname>Patton</surname><given-names>W. F.</given-names></name>; <name><surname>Chiang</surname><given-names>E. T.</given-names></name>; <name><surname>Hechtman</surname><given-names>H. B.</given-names></name>; <name><surname>Shepro</surname><given-names>D.</given-names></name> (<year>1996</year>) <article-title>Filamin translocation
is an early endothelial cell inflammatory response to bradykinin:
regulation by calcium, protein kinases, and protein phosphatases</article-title>. <source>J. Cell. Biochem.</source>
<volume>62</volume>, <fpage>383</fpage>â<lpage>396</lpage><pub-id pub-id-type="doi">10.1002/(SICI)1097-4644(199609)62:3&lt;383::AID-JCB8&gt;3.0.CO;2-N</pub-id>.<pub-id pub-id-type="pmid">8872609</pub-id></mixed-citation>
      </ref>
      <ref id="ref52">
        <mixed-citation publication-type="journal" id="cit52"><name><surname>Wang</surname><given-names>Q.</given-names></name>; <name><surname>Patton</surname><given-names>W. F.</given-names></name>; <name><surname>Hechtman</surname><given-names>H. B.</given-names></name>; <name><surname>Shepro</surname><given-names>D.</given-names></name> (<year>1997</year>) <article-title>Activation of endothelial
cell kinin receptors leads to intracellular calcium increases and
filamin translocation: regulation by protein kinase C</article-title>. <source>Cell. Signalling</source>
<volume>9</volume>, <fpage>595</fpage>â<lpage>602</lpage><pub-id pub-id-type="doi">10.1016/S0898-6568(97)00051-X</pub-id>.<pub-id pub-id-type="pmid">9429763</pub-id></mixed-citation>
      </ref>
      <ref id="ref53">
        <mixed-citation publication-type="journal" id="cit53"><name><surname>GÃ³mez-MoutÃ³n</surname><given-names>C.</given-names></name>; <name><surname>Fischer</surname><given-names>T.</given-names></name>; <name><surname>Peregil</surname><given-names>R. M.</given-names></name>; <name><surname>JimÃ©nez-Baranda</surname><given-names>S.</given-names></name>; <name><surname>Stossel</surname><given-names>T. P.</given-names></name>; <name><surname>Nakamura</surname><given-names>F.</given-names></name>; <name><surname>MaÃ±es</surname><given-names>S.</given-names></name> (<year>2015</year>) <article-title>Filamin A
interaction with the CXCR4 third intracellular loop regulates endocytosis
and signaling of WT and WHIM-like receptors</article-title>. <source>Blood</source>
<volume>125</volume>, <fpage>1116</fpage>â<lpage>1125</lpage><pub-id pub-id-type="doi">10.1182/blood-2014-09-601807</pub-id>.<pub-id pub-id-type="pmid">25355818</pub-id></mixed-citation>
      </ref>
      <ref id="ref54">
        <mixed-citation publication-type="journal" id="cit54"><name><surname>Singh</surname><given-names>S. N.</given-names></name>; <name><surname>Bakshi</surname><given-names>K.</given-names></name>; <name><surname>Mercier</surname><given-names>R. W.</given-names></name>; <name><surname>Makriyannis</surname><given-names>A.</given-names></name>; <name><surname>Pavlopoulos</surname><given-names>S.</given-names></name> (<year>2011</year>) <article-title>Binding between a distal C-terminus fragment of cannabinoid
receptor 1 and arrestin-2</article-title>. <source>Biochemistry</source>
<volume>50</volume>, <fpage>2223</fpage>â<lpage>2234</lpage><pub-id pub-id-type="doi">10.1021/bi1018144</pub-id>.<pub-id pub-id-type="pmid">21306178</pub-id></mixed-citation>
      </ref>
      <ref id="ref55">
        <mixed-citation publication-type="journal" id="cit55"><name><surname>Kamato</surname><given-names>D.</given-names></name>; <name><surname>Burch</surname><given-names>M. L.</given-names></name>; <name><surname>Osman</surname><given-names>N.</given-names></name>; <name><surname>Zheng</surname><given-names>W.</given-names></name>; <name><surname>Little</surname><given-names>P. J.</given-names></name> (<year>2013</year>) <article-title>Therapeutic
implications of endothelin and thrombin G-protein-coupled receptor
transactivation of tyrosine and serine/threonine kinase cell surface
receptors</article-title>. <source>J. Pharm. Pharmacol.</source>
<volume>65</volume>, <fpage>465</fpage>â<lpage>473</lpage><pub-id pub-id-type="doi">10.1111/j.2042-7158.2012.01577.x</pub-id>.<pub-id pub-id-type="pmid">23488775</pub-id></mixed-citation>
      </ref>
      <ref id="ref56">
        <mixed-citation publication-type="journal" id="cit56"><name><surname>Doyon</surname><given-names>P.</given-names></name>; <name><surname>Servant</surname><given-names>M. J.</given-names></name> (<year>2010</year>) <article-title>Tumor necrosis factor
receptor-associated factor-6
and ribosomal S6 kinase intracellular pathways link the angiotensin
II AT1 receptor to the phosphorylation and activation of the IkappaB
kinase complex in vascular smooth muscle cells</article-title>. <source>J. Biol. Chem.</source>
<volume>285</volume>, <fpage>30708</fpage>â<lpage>30718</lpage><pub-id pub-id-type="doi">10.1074/jbc.M110.126433</pub-id>.<pub-id pub-id-type="pmid">20659889</pub-id></mixed-citation>
      </ref>
      <ref id="ref57">
        <mixed-citation publication-type="journal" id="cit57"><name><surname>Xiao</surname><given-names>K.</given-names></name>; <name><surname>McClatchy</surname><given-names>D. B.</given-names></name>; <name><surname>Shukla</surname><given-names>A. K.</given-names></name>; <name><surname>Zhao</surname><given-names>Y.</given-names></name>; <name><surname>Chen</surname><given-names>M.</given-names></name>; <name><surname>Shenoy</surname><given-names>S. K.</given-names></name>; <name><surname>Yates</surname><given-names>J. R.</given-names><suffix>3rd.</suffix></name>; <name><surname>Lefkowitz</surname><given-names>R. J.</given-names></name> (<year>2007</year>) <article-title>Functional
specialization of beta-arrestin interactions revealed by proteomic
analysis</article-title>. <source>Proc. Natl. Acad. Sci. U. S. A.</source>
<volume>104</volume>, <fpage>12011</fpage>â<lpage>12016</lpage><pub-id pub-id-type="doi">10.1073/pnas.0704849104</pub-id>.<pub-id pub-id-type="pmid">17620599</pub-id></mixed-citation>
      </ref>
      <ref id="ref58">
        <mixed-citation publication-type="journal" id="cit58"><name><surname>Sayner</surname><given-names>S. L.</given-names></name>; <name><surname>Balczon</surname><given-names>R.</given-names></name>; <name><surname>Frank</surname><given-names>D. W.</given-names></name>; <name><surname>Cooper</surname><given-names>D. M.</given-names></name>; <name><surname>Stevens</surname><given-names>T.</given-names></name> (<year>2011</year>) <article-title>Filamin A
is a phosphorylation target of membrane but not cytosolic adenylyl
cyclase activity</article-title>. <source>Am. J. Physiol. Lung Cell
Mol. Physiol.</source>
<volume>301</volume>, <fpage>L117</fpage>â<lpage>124</lpage><pub-id pub-id-type="doi">10.1152/ajplung.00417.2009</pub-id>.<pub-id pub-id-type="pmid">21478251</pub-id></mixed-citation>
      </ref>
      <ref id="ref59">
        <mixed-citation publication-type="journal" id="cit59"><name><surname>Zhang</surname><given-names>J.</given-names></name>; <name><surname>Neal</surname><given-names>J.</given-names></name>; <name><surname>Lian</surname><given-names>G.</given-names></name>; <name><surname>Shi</surname><given-names>B.</given-names></name>; <name><surname>Ferland</surname><given-names>R. J.</given-names></name>; <name><surname>Sheen</surname><given-names>V.</given-names></name> (<year>2012</year>) <article-title>Brefeldin A-inhibited guanine exchange
factor 2 regulates filamin
A phosphorylation and neuronal migration</article-title>. <source>J.
Neurosci.</source>
<volume>32</volume>, <fpage>12619</fpage>â<lpage>12629</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.1063-12.2012</pub-id>.<pub-id pub-id-type="pmid">22956851</pub-id></mixed-citation>
      </ref>
      <ref id="ref60">
        <mixed-citation publication-type="journal" id="cit60"><name><surname>Dulin</surname><given-names>N. O.</given-names></name>; <name><surname>Niu</surname><given-names>J.</given-names></name>; <name><surname>Browning</surname><given-names>D. D</given-names></name>; <name><surname>Ye</surname><given-names>R. D.</given-names></name>; <name><surname>Voyno-Yasenetskaya</surname><given-names>T.</given-names></name> (<year>2001</year>) <article-title>Cyclic AMP-independent
activation of protein kinase A by vasoactive peptides</article-title>. <source>J. Biol. Chem.</source>
<volume>276</volume>, <fpage>20827</fpage>â<lpage>20830</lpage><pub-id pub-id-type="doi">10.1074/jbc.C100195200</pub-id>.<pub-id pub-id-type="pmid">11331270</pub-id></mixed-citation>
      </ref>
      <ref id="ref61">
        <mixed-citation publication-type="journal" id="cit61"><name><surname>Kim</surname><given-names>K. M.</given-names></name>; <name><surname>Gainetdinov</surname><given-names>R. R.</given-names></name>; <name><surname>Laporte</surname><given-names>S. A.</given-names></name>; <name><surname>Caron</surname><given-names>M. G.</given-names></name>; <name><surname>Barak</surname><given-names>L. S.</given-names></name> (<year>2005</year>) <article-title>G protein-coupled
receptor kinase regulates dopamine D3 receptor signaling by modulating
the stability of a receptor-filamin-beta-arrestin complex. A case
of autoreceptor regulation</article-title>. <source>J. Biol. Chem.</source>
<volume>280</volume>, <fpage>12774</fpage>â<lpage>12780</lpage><pub-id pub-id-type="doi">10.1074/jbc.M408901200</pub-id>.<pub-id pub-id-type="pmid">15687500</pub-id></mixed-citation>
      </ref>
      <ref id="ref62">
        <mixed-citation publication-type="journal" id="cit62"><name><surname>Scott</surname><given-names>M. G.</given-names></name>; <name><surname>Pierotti</surname><given-names>V.</given-names></name>; <name><surname>Storez</surname><given-names>H.</given-names></name>; <name><surname>Lindberg</surname><given-names>E.</given-names></name>; <name><surname>Thuret</surname><given-names>A.</given-names></name>; <name><surname>Muntaner</surname><given-names>O.</given-names></name>; <name><surname>LabbÃ©-JulliÃ©</surname><given-names>C.</given-names></name>; <name><surname>Pitcher</surname><given-names>J. A.</given-names></name>; <name><surname>Marullo</surname><given-names>S.</given-names></name> (<year>2006</year>) <article-title>Cooperative regulation of extracellular
signal-regulated
kinase activation and cell shape change by filamin A and beta-arrestins</article-title>. <source>Mol. Cell. Biol.</source>
<volume>26</volume>, <fpage>3432</fpage>â<lpage>3445</lpage><pub-id pub-id-type="doi">10.1128/MCB.26.9.3432-3445.2006</pub-id>.<pub-id pub-id-type="pmid">16611986</pub-id></mixed-citation>
      </ref>
      <ref id="ref63">
        <mixed-citation publication-type="journal" id="cit63"><name><surname>Feierler</surname><given-names>J.</given-names></name>; <name><surname>Wirth</surname><given-names>M.</given-names></name>; <name><surname>Welte</surname><given-names>B.</given-names></name>; <name><surname>SchÃ¼ssler</surname><given-names>S.</given-names></name>; <name><surname>Jochum</surname><given-names>M.</given-names></name>; <name><surname>Faussner</surname><given-names>A.</given-names></name> (<year>2011</year>) <article-title>Helix 8 plays a crucial
role in bradykinin
B(2) receptor trafficking and signaling</article-title>. <source>J.
Biol. Chem.</source>
<volume>286</volume>, <fpage>43282</fpage>â<lpage>93</lpage><pub-id pub-id-type="doi">10.1074/jbc.M111.256909</pub-id>.<pub-id pub-id-type="pmid">22016392</pub-id></mixed-citation>
      </ref>
      <ref id="ref64">
        <mixed-citation publication-type="journal" id="cit64"><name><surname>Zhang</surname><given-names>X.</given-names></name>; <name><surname>Wang</surname><given-names>H.</given-names></name>; <name><surname>Duvernay</surname><given-names>M. T.</given-names></name>; <name><surname>Zhu</surname><given-names>S.</given-names></name>; <name><surname>Wu</surname><given-names>G.</given-names></name> (<year>2013</year>) <article-title>The angiotensin
II type 1 receptor C-terminal Lys residues interact with tubulin and
modulate receptor export trafficking</article-title>. <source>PLoS One</source>
<volume>8</volume>, <fpage>e57805</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0057805</pub-id>.<pub-id pub-id-type="pmid">23451270</pub-id></mixed-citation>
      </ref>
      <ref id="ref65">
        <mixed-citation publication-type="journal" id="cit65"><name><surname>Jaakola</surname><given-names>V. P.</given-names></name>; <name><surname>Prilusky</surname><given-names>J.</given-names></name>; <name><surname>Sussman</surname><given-names>J. L.</given-names></name>; <name><surname>Goldman</surname><given-names>A.</given-names></name> (<year>2005</year>) <article-title>G protein-coupled receptors
show unusual patterns of intrinsic unfolding</article-title>. <source>Protein Eng., Des. Sel.</source>
<volume>18</volume>, <fpage>103</fpage>â<lpage>110</lpage><pub-id pub-id-type="doi">10.1093/protein/gzi004</pub-id>.<pub-id pub-id-type="pmid">15790574</pub-id></mixed-citation>
      </ref>
      <ref id="ref66">
        <mixed-citation publication-type="journal" id="cit66"><name><surname>Unal</surname><given-names>H.</given-names></name>; <name><surname>Karnik</surname><given-names>S. S.</given-names></name> (<year>2012</year>) <article-title>Domain coupling in GPCRs: the engine for induced conformational
changes</article-title>. <source>Trends Pharmacol. Sci.</source>
<volume>33</volume>, <fpage>79</fpage>â<lpage>88</lpage><pub-id pub-id-type="doi">10.1016/j.tips.2011.09.007</pub-id>.<pub-id pub-id-type="pmid">22037017</pub-id></mixed-citation>
      </ref>
      <ref id="ref67">
        <mixed-citation publication-type="journal" id="cit67"><name><surname>Venkatakrishnan</surname><given-names>A. J.</given-names></name>; <name><surname>Deupi</surname><given-names>X.</given-names></name>; <name><surname>Lebon</surname><given-names>G.</given-names></name>; <name><surname>Tate</surname><given-names>C. G.</given-names></name>; <name><surname>Schertler</surname><given-names>G. F.</given-names></name>; <name><surname>Babu</surname><given-names>M. M.</given-names></name> (<year>2013</year>) <article-title>Molecular signatures
of G-protein-coupled receptors</article-title>. <source>Nature</source>
<volume>494</volume>, <fpage>185</fpage>â<lpage>194</lpage><pub-id pub-id-type="doi">10.1038/nature11896</pub-id>.<pub-id pub-id-type="pmid">23407534</pub-id></mixed-citation>
      </ref>
      <ref id="ref68">
        <mixed-citation publication-type="journal" id="cit68"><name><surname>Dyson</surname><given-names>H. J.</given-names></name>; <name><surname>Wright</surname><given-names>P. E.</given-names></name> (<year>2005</year>) <article-title>Intrinsically unstructured
proteins and their functions</article-title>. <source>Nat. Rev. Mol.
Cell Biol.</source>
<volume>6</volume>, <fpage>197</fpage>â<lpage>208</lpage><pub-id pub-id-type="doi">10.1038/nrm1589</pub-id>.<pub-id pub-id-type="pmid">15738986</pub-id></mixed-citation>
      </ref>
      <ref id="ref69">
        <mixed-citation publication-type="journal" id="cit69"><name><surname>Dunker</surname><given-names>A.
K.</given-names></name>; <name><surname>Lawson</surname><given-names>J. D.</given-names></name>; <name><surname>Brown</surname><given-names>C. J.</given-names></name>; <name><surname>Williams</surname><given-names>R. M.</given-names></name>; <name><surname>Romero</surname><given-names>P.</given-names></name>; <name><surname>Oh</surname><given-names>J. S.</given-names></name>; <name><surname>Oldfield</surname><given-names>C. J.</given-names></name>; <name><surname>Campen</surname><given-names>A. M.</given-names></name>; <name><surname>Ratliff</surname><given-names>C. M.</given-names></name>; <name><surname>Hipps</surname><given-names>K. W.</given-names></name>; <name><surname>Ausio</surname><given-names>J.</given-names></name>; <name><surname>Nissen</surname><given-names>M. S.</given-names></name>; <name><surname>Reeves</surname><given-names>R.</given-names></name>; <name><surname>Kang</surname><given-names>C.</given-names></name>; <name><surname>Kissinger</surname><given-names>C. R.</given-names></name>; <name><surname>Bailey</surname><given-names>R. W.</given-names></name>; <name><surname>Griswold</surname><given-names>M. D.</given-names></name>; <name><surname>Chiu</surname><given-names>W.</given-names></name>; <name><surname>Garner</surname><given-names>E. C.</given-names></name>; <name><surname>Obradovic</surname><given-names>Z.</given-names></name> (<year>2001</year>) <article-title>Intrinsically
disordered protein</article-title>. <source>J. Mol. Graphics Modell.</source>
<volume>19</volume>, <fpage>26</fpage>â<lpage>59</lpage><pub-id pub-id-type="doi">10.1016/S1093-3263(00)00138-8</pub-id>.</mixed-citation>
      </ref>
      <ref id="ref70">
        <mixed-citation publication-type="journal" id="cit70"><name><surname>Light</surname><given-names>S.</given-names></name>; <name><surname>Sagit</surname><given-names>R.</given-names></name>; <name><surname>Ithychanda</surname><given-names>S. S.</given-names></name>; <name><surname>Qin</surname><given-names>J.</given-names></name>; <name><surname>Elofsson</surname><given-names>A.</given-names></name> (<year>2012</year>) <article-title>The evolution
of filamin-a protein domain repeat perspective</article-title>. <source>J. Struct. Biol.</source>
<volume>179</volume>, <fpage>289</fpage>â<lpage>298</lpage><pub-id pub-id-type="doi">10.1016/j.jsb.2012.02.010</pub-id>.<pub-id pub-id-type="pmid">22414427</pub-id></mixed-citation>
      </ref>
      <ref id="ref71">
        <mixed-citation publication-type="journal" id="cit71"><name><surname>Tompa</surname><given-names>P.</given-names></name>; <name><surname>Davey</surname><given-names>N. E.</given-names></name>; <name><surname>Gibson</surname><given-names>T. J.</given-names></name>; <name><surname>Babu</surname><given-names>M. M.</given-names></name> (<year>2014</year>) <article-title>A million
peptide
motifs for the molecular biologist</article-title>. <source>Mol. Cell</source>
<volume>55</volume>, <fpage>161</fpage>â<lpage>169</lpage><pub-id pub-id-type="doi">10.1016/j.molcel.2014.05.032</pub-id>.<pub-id pub-id-type="pmid">25038412</pub-id></mixed-citation>
      </ref>
      <ref id="ref72">
        <mixed-citation publication-type="journal" id="cit72"><name><surname>Travis</surname><given-names>M. A.</given-names></name>; <name><surname>van der Flier</surname><given-names>A.</given-names></name>; <name><surname>Kammerer</surname><given-names>R. A.</given-names></name>; <name><surname>Paul Mould</surname><given-names>A. P.</given-names></name>; <name><surname>Sonnenberg</surname><given-names>A.</given-names></name>; <name><surname>Humphries</surname><given-names>M. J.</given-names></name> (<year>2004</year>) <article-title>Interaction of filamin A with the
integrin beta 7 cytoplasmic domain: role of alternative splicing and
phosphorylation</article-title>. <source>FEBS Lett.</source>
<volume>569</volume>, <fpage>185</fpage>â<lpage>190</lpage><pub-id pub-id-type="doi">10.1016/j.febslet.2004.04.099</pub-id>.<pub-id pub-id-type="pmid">15225631</pub-id></mixed-citation>
      </ref>
      <ref id="ref73">
        <mixed-citation publication-type="journal" id="cit73"><name><surname>van
der Flier</surname><given-names>A.</given-names></name>; <name><surname>Kuikman</surname><given-names>I.</given-names></name>; <name><surname>Kramer</surname><given-names>D.</given-names></name>; <name><surname>Geerts</surname><given-names>D.</given-names></name>; <name><surname>Kreft</surname><given-names>M.</given-names></name>; <name><surname>Takafuta</surname><given-names>T.</given-names></name>; <name><surname>Shapiro</surname><given-names>S. S.</given-names></name>; <name><surname>Sonnenberg</surname><given-names>A.</given-names></name> (<year>2002</year>) <article-title>Different
splice variants of filamin-B affect myogenesis, subcellular distribution,
and determine binding to integrin [beta] subunits</article-title>. <source>J. Cell Biol.</source>
<volume>156</volume>, <fpage>361</fpage>â<lpage>376</lpage><pub-id pub-id-type="doi">10.1083/jcb.200103037</pub-id>.<pub-id pub-id-type="pmid">11807098</pub-id></mixed-citation>
      </ref>
    </ref-list>
  </back>
</article>

</metadata></record></GetRecord></OAI-PMH>